US8399643B2
(en)
|
2009-02-26 |
2013-03-19 |
Transposagen Biopharmaceuticals, Inc. |
Nucleic acids encoding hyperactive PiggyBac transposases
|
DK3241435T3
(da)
|
2009-07-08 |
2021-08-23 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9457077B2
(en)
|
2009-11-18 |
2016-10-04 |
Katherine Rose Kovarik |
Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
|
US9585920B2
(en)
|
2011-02-04 |
2017-03-07 |
Katherine Rose Kovarik |
Method and system for treating cancer cachexia
|
US9730967B2
(en)
|
2011-02-04 |
2017-08-15 |
Katherine Rose Kovarik |
Method and system for treating cancer cachexia
|
US11419903B2
(en)
|
2015-11-30 |
2022-08-23 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
US10512661B2
(en)
|
2011-02-04 |
2019-12-24 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
|
US11951139B2
(en)
|
2015-11-30 |
2024-04-09 |
Seed Health, Inc. |
Method and system for reducing the likelihood of osteoporosis
|
US10111913B2
(en)
|
2011-02-04 |
2018-10-30 |
Joseph E. Kovarik |
Method of reducing the likelihood of skin cancer in an individual human being
|
US10010568B2
(en)
|
2011-02-04 |
2018-07-03 |
Katherine Rose Kovarik |
Method and system for reducing the likelihood of a spirochetes infection in a human being
|
US10245288B2
(en)
|
2011-02-04 |
2019-04-02 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
|
US11844720B2
(en)
|
2011-02-04 |
2023-12-19 |
Seed Health, Inc. |
Method and system to reduce the likelihood of dental caries and halitosis
|
US11523934B2
(en)
|
2011-02-04 |
2022-12-13 |
Seed Health, Inc. |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US10835560B2
(en)
|
2013-12-20 |
2020-11-17 |
Joseph E. Kovarik |
Reducing the likelihood of skin cancer in an individual human being
|
US10940169B2
(en)
|
2015-11-30 |
2021-03-09 |
Joseph E. Kovarik |
Method for reducing the likelihood of developing cancer in an individual human being
|
US11191665B2
(en)
|
2011-02-04 |
2021-12-07 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
|
US10687975B2
(en)
|
2011-02-04 |
2020-06-23 |
Joseph E. Kovarik |
Method and system to facilitate the growth of desired bacteria in a human's mouth
|
US9987224B2
(en)
|
2011-02-04 |
2018-06-05 |
Joseph E. Kovarik |
Method and system for preventing migraine headaches, cluster headaches and dizziness
|
US11951140B2
(en)
|
2011-02-04 |
2024-04-09 |
Seed Health, Inc. |
Modulation of an individual's gut microbiome to address osteoporosis and bone disease
|
US11357722B2
(en)
|
2011-02-04 |
2022-06-14 |
Seed Health, Inc. |
Method and system for preventing sore throat in humans
|
US10548761B2
(en)
|
2011-02-04 |
2020-02-04 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of colorectal cancer in a human being
|
US10086018B2
(en)
|
2011-02-04 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of colorectal cancer in a human being
|
US11273187B2
(en)
|
2015-11-30 |
2022-03-15 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing depression in an individual
|
US10314865B2
(en)
|
2011-02-04 |
2019-06-11 |
Katherine Rose Kovarik |
Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
|
US10085938B2
(en)
|
2011-02-04 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for preventing sore throat in humans
|
US10583033B2
(en)
|
2011-02-04 |
2020-03-10 |
Katherine Rose Kovarik |
Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
|
US10842834B2
(en)
|
2016-01-06 |
2020-11-24 |
Joseph E. Kovarik |
Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
|
JP6165723B2
(ja)
|
2011-06-30 |
2017-07-19 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
B型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
JP5813880B2
(ja)
|
2011-09-19 |
2015-11-17 |
カイマブ・リミテッド |
ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US10465042B2
(en)
|
2011-12-02 |
2019-11-05 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
IN2014MN00974A
(sl)
|
2011-12-16 |
2015-04-24 |
Targetgene Biotechnologies Ltd |
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
EP2847335B1
(en)
|
2012-04-25 |
2018-06-27 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US10564147B2
(en)
|
2012-05-25 |
2020-02-18 |
The Regents Of The University Of California |
Microfluidic systems for particle trapping and separation using cavity acoustic transducers
|
PE20150336A1
(es)
|
2012-05-25 |
2015-03-25 |
Univ California |
Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn
|
KR20150023670A
(ko)
*
|
2012-06-12 |
2015-03-05 |
제넨테크, 인크. |
조건적 녹아웃 대립유전자의 생성 방법 및 이를 위한 조성물
|
US20150225734A1
(en)
|
2012-06-19 |
2015-08-13 |
Regents Of The University Of Minnesota |
Gene targeting in plants using dna viruses
|
EP3808844A1
(en)
|
2012-07-25 |
2021-04-21 |
The Broad Institute, Inc. |
Inducible dna binding proteins and genome perturbation tools and applications thereof
|
KR102389278B1
(ko)
*
|
2012-10-23 |
2022-04-26 |
주식회사 툴젠 |
표적 DNA에 특이적인 가이드 RNA 및 Cas 단백질을 암호화하는 핵산 또는 Cas 단백질을 포함하는, 표적 DNA를 절단하기 위한 조성물 및 이의 용도
|
CN116064533A
(zh)
*
|
2012-10-23 |
2023-05-05 |
基因工具股份有限公司 |
用于切割靶dna的组合物及其用途
|
US10415024B2
(en)
|
2012-11-16 |
2019-09-17 |
Poseida Therapeutics, Inc. |
Site-specific enzymes and methods of use
|
SG10201704008RA
(en)
|
2012-11-27 |
2017-06-29 |
The Children's Medical Center Corp |
Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction
|
KR101844123B1
(ko)
|
2012-12-06 |
2018-04-02 |
시그마-알드리치 컴퍼니., 엘엘씨 |
Crispr-기초된 유전체 변형과 조절
|
EP3252160B1
(en)
*
|
2012-12-12 |
2020-10-28 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
ES2786193T3
(es)
|
2012-12-12 |
2020-10-09 |
Broad Inst Inc |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
|
US8697359B1
(en)
*
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
ES2553782T3
(es)
*
|
2012-12-12 |
2015-12-11 |
The Broad Institute, Inc. |
Ingeniería de sistemas, métodos y composiciones de guía optimizadas para manipulación de secuencias
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
EP2931899A1
(en)
*
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
MX2015007550A
(es)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
|
EP2848690B1
(en)
*
|
2012-12-12 |
2020-08-19 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
RU2699523C2
(ru)
*
|
2012-12-17 |
2019-09-05 |
Президент Энд Фэллоуз Оф Харвард Коллидж |
Рнк-направляемая инженерия генома человека
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
WO2014124226A1
(en)
|
2013-02-07 |
2014-08-14 |
The Rockefeller University |
Sequence specific antimicrobials
|
US11135273B2
(en)
|
2013-02-07 |
2021-10-05 |
The Rockefeller University |
Sequence specific antimicrobials
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
US11466306B2
(en)
*
|
2013-02-14 |
2022-10-11 |
Osaka University |
Method for isolating specific genomic regions with use of molecule capable of specifically binding to endogenous DNA sequence
|
ES2904803T3
(es)
|
2013-02-20 |
2022-04-06 |
Regeneron Pharma |
Modificación genética de ratas
|
EP2922393B2
(en)
|
2013-02-27 |
2022-12-28 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Gene editing in the oocyte by cas9 nucleases
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
ES2901396T3
(es)
|
2013-03-14 |
2022-03-22 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos a ácido nucleico
|
CN113563476A
(zh)
*
|
2013-03-15 |
2021-10-29 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
US9957515B2
(en)
|
2013-03-15 |
2018-05-01 |
Cibus Us Llc |
Methods and compositions for targeted gene modification
|
US20140273235A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Regents Of The University Of Minnesota |
ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
IL290273B2
(en)
*
|
2013-03-15 |
2024-03-01 |
Cibus Us Llc |
Methods and compositions for increasing the efficiency of targeted gene modification through the use of gene repair with oligonucleotides - mediators
|
MY191390A
(en)
|
2013-03-15 |
2022-06-22 |
Cibus Us Llc |
Methods and compositions for increasing efficiency of increased efficiency of targeted gene modification using oligonucleotide-mediated gene repair
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
US20140349400A1
(en)
*
|
2013-03-15 |
2014-11-27 |
Massachusetts Institute Of Technology |
Programmable Modification of DNA
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
PT3456831T
(pt)
|
2013-04-16 |
2021-09-10 |
Regeneron Pharma |
Modificação alvejada do genoma de rato
|
US20160186208A1
(en)
*
|
2013-04-16 |
2016-06-30 |
Whitehead Institute For Biomedical Research |
Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
EP2994531B1
(en)
|
2013-05-10 |
2018-03-28 |
Sangamo Therapeutics, Inc. |
Delivery methods and compositions for nuclease-mediated genome engineering
|
WO2014186435A2
(en)
|
2013-05-14 |
2014-11-20 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for reducing neointima formation
|
CN116083487A
(zh)
*
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
US11414695B2
(en)
*
|
2013-05-29 |
2022-08-16 |
Agilent Technologies, Inc. |
Nucleic acid enrichment using Cas9
|
EP3004349B1
(en)
*
|
2013-05-29 |
2018-03-28 |
Cellectis S.A. |
A method for producing precise dna cleavage using cas9 nickase activity
|
US11685935B2
(en)
*
|
2013-05-29 |
2023-06-27 |
Cellectis |
Compact scaffold of Cas9 in the type II CRISPR system
|
US9267135B2
(en)
*
|
2013-06-04 |
2016-02-23 |
President And Fellows Of Harvard College |
RNA-guided transcriptional regulation
|
EP3603679B1
(en)
*
|
2013-06-04 |
2022-08-10 |
President and Fellows of Harvard College |
Rna-guided transcriptional regulation
|
US9982277B2
(en)
|
2013-06-11 |
2018-05-29 |
The Regents Of The University Of California |
Methods and compositions for target DNA modification
|
AU2014279694B2
(en)
*
|
2013-06-14 |
2020-07-23 |
Cellectis |
Methods for non-transgenic genome editing in plants
|
KR20160034901A
(ko)
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물
|
ES2777217T3
(es)
*
|
2013-06-17 |
2020-08-04 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias
|
DK3011031T3
(da)
*
|
2013-06-17 |
2020-12-21 |
Broad Inst Inc |
Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
|
DK3011032T3
(da)
|
2013-06-17 |
2020-01-20 |
Broad Inst Inc |
Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler
|
SG11201510286QA
(en)
*
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
KR20160029112A
(ko)
*
|
2013-07-09 |
2016-03-14 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
멀티플렉스 rna-가이드된 게놈 조작
|
BR112016000571B1
(pt)
|
2013-07-10 |
2023-12-26 |
President And Fellows Of Harvard College |
Métodos in vitro para modular a expressão e para alterar um ou mais ácidos nucleicos alvo em uma célula simultaneamente com a regulação da expressão de um ou mais ácidos nucleicos alvo em uma célula, bem como célula de levedura ou bactéria compreendendo ácidos nucleicos
|
US9663782B2
(en)
*
|
2013-07-19 |
2017-05-30 |
Larix Bioscience Llc |
Methods and compositions for producing double allele knock outs
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
WO2015017866A1
(en)
|
2013-08-02 |
2015-02-05 |
Enevolv, Inc. |
Processes and host cells for genome, pathway, and biomolecular engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
LT3036327T
(lt)
|
2013-08-22 |
2019-06-25 |
Pioneer Hi-Bred International, Inc. |
Genomo modifikacijos, panaudojant nukreipiančias polinukleotido/cas endonukleazės sistemas, ir panaudojimo būdai
|
EP3041498B1
(en)
*
|
2013-09-05 |
2022-02-16 |
Massachusetts Institute of Technology |
Tuning microbial populations with programmable nucleases
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9340800B2
(en)
*
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
US9388430B2
(en)
*
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
RU2675824C2
(ru)
|
2013-09-11 |
2018-12-25 |
Игл Байолоджикс, Инк. |
Жидкие белковые составы, содержащие ионные жидкости
|
CN105637087A
(zh)
*
|
2013-09-18 |
2016-06-01 |
科马布有限公司 |
方法、细胞与生物体
|
NL2013554B1
(en)
|
2013-10-01 |
2016-01-08 |
Kymab Ltd |
Animal models and therapeutic molecules.
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
BR102014027466B1
(pt)
*
|
2013-11-04 |
2022-09-27 |
Dow Agrosciences Llc |
Molécula de ácido nucleico recombinante, método para produzir uma célula vegetal transgênica e usos de uma planta de soja, parte de planta de soja ou célula de planta de soja transgênica
|
WO2015069682A2
(en)
*
|
2013-11-05 |
2015-05-14 |
President And Fellows Of Harvard College |
Precise microbiota engineering at the cellular level
|
US11326209B2
(en)
*
|
2013-11-07 |
2022-05-10 |
Massachusetts Institute Of Technology |
Cell-based genomic recorded accumulative memory
|
CN106459995B
(zh)
|
2013-11-07 |
2020-02-21 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
CA2930877A1
(en)
*
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
CN105980568B
(zh)
|
2013-12-11 |
2019-12-03 |
瑞泽恩制药公司 |
用于靶向修饰基因组的方法和组合物
|
SI3080279T1
(sl)
|
2013-12-11 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano spremembo genoma
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
CN111269902A
(zh)
*
|
2013-12-12 |
2020-06-12 |
布罗德研究所有限公司 |
Crispr-cas系统和组合物的递送及用途
|
KR20160089526A
(ko)
*
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
입자 전달 성분을 이용한 표적 장애 및 질병에 대한 crispr-cas 시스템 및 조성물의 전달, 이용 및 치료 적용
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
US9994831B2
(en)
*
|
2013-12-12 |
2018-06-12 |
The Regents Of The University Of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
AU2014361834B2
(en)
|
2013-12-12 |
2020-10-22 |
Massachusetts Institute Of Technology |
CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
|
DK3079725T3
(da)
*
|
2013-12-12 |
2020-01-20 |
Broad Inst Inc |
Administration, brug og terapeutiske anvendelser af crispr-cas-systemerne og sammensætninger til genomredigering
|
JP6625055B2
(ja)
*
|
2013-12-12 |
2020-01-08 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
|
AU2014363476A1
(en)
*
|
2013-12-13 |
2016-06-23 |
Cellectis |
Cas9 nuclease platform for microalgae genome engineering
|
JP2017505756A
(ja)
|
2013-12-13 |
2017-02-23 |
ザ ジェネラル ホスピタル コーポレイション |
可溶性高分子量(hmw)タウ種およびその用途
|
US20150191744A1
(en)
*
|
2013-12-17 |
2015-07-09 |
University Of Massachusetts |
Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
MX2016007797A
(es)
|
2013-12-19 |
2016-09-07 |
Amyris Inc |
Metodos para integracion genomica.
|
SG10201804439PA
(en)
|
2013-12-20 |
2018-06-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
US11026982B2
(en)
|
2015-11-30 |
2021-06-08 |
Joseph E. Kovarik |
Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
|
US11980643B2
(en)
|
2013-12-20 |
2024-05-14 |
Seed Health, Inc. |
Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
|
US11529379B2
(en)
|
2013-12-20 |
2022-12-20 |
Seed Health, Inc. |
Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
US11213552B2
(en)
|
2015-11-30 |
2022-01-04 |
Joseph E. Kovarik |
Method for treating an individual suffering from a chronic infectious disease and cancer
|
US11833177B2
(en)
|
2013-12-20 |
2023-12-05 |
Seed Health, Inc. |
Probiotic to enhance an individual's skin microbiome
|
US11839632B2
(en)
|
2013-12-20 |
2023-12-12 |
Seed Health, Inc. |
Topical application of CRISPR-modified bacteria to treat acne vulgaris
|
US11672835B2
(en)
|
2013-12-20 |
2023-06-13 |
Seed Health, Inc. |
Method for treating individuals having cancer and who are receiving cancer immunotherapy
|
US11642382B2
(en)
|
2013-12-20 |
2023-05-09 |
Seed Health, Inc. |
Method for treating an individual suffering from bladder cancer
|
US11826388B2
(en)
|
2013-12-20 |
2023-11-28 |
Seed Health, Inc. |
Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
|
US11969445B2
(en)
|
2013-12-20 |
2024-04-30 |
Seed Health, Inc. |
Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
|
CN106103706B
(zh)
*
|
2013-12-26 |
2021-08-24 |
通用医疗公司 |
多重引导rna
|
US9963689B2
(en)
|
2013-12-31 |
2018-05-08 |
The Regents Of The University Of California |
Cas9 crystals and methods of use thereof
|
CN106133141B
(zh)
*
|
2014-01-08 |
2021-08-20 |
哈佛学院董事及会员团体 |
Rna引导的基因驱动
|
US20150197759A1
(en)
*
|
2014-01-14 |
2015-07-16 |
Lam Therapeutics, Inc. |
Mutagenesis methods
|
WO2015112896A2
(en)
*
|
2014-01-24 |
2015-07-30 |
North Carolina State University |
Methods and compositions for sequences guiding cas9 targeting
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
WO2015113063A1
(en)
|
2014-01-27 |
2015-07-30 |
Georgia Tech Research Corporation |
Methods and systems for identifying crispr/cas off-target sites
|
US11315659B2
(en)
*
|
2014-01-27 |
2022-04-26 |
Georgia Tech Research Corporation |
Methods and systems for identifying nucleotide-guided nuclease off-target sites
|
US9850525B2
(en)
*
|
2014-01-29 |
2017-12-26 |
Agilent Technologies, Inc. |
CAS9-based isothermal method of detection of specific DNA sequence
|
EP3102722B1
(en)
*
|
2014-02-04 |
2020-08-26 |
Jumpcode Genomics, Inc. |
Genome fractioning
|
CN111705365A
(zh)
*
|
2014-02-11 |
2020-09-25 |
科罗拉多州立大学董事会(法人团体) |
Crispr支持的多路基因组工程化
|
US10287590B2
(en)
*
|
2014-02-12 |
2019-05-14 |
Dna2.0, Inc. |
Methods for generating libraries with co-varying regions of polynuleotides for genome modification
|
CA2939621C
(en)
*
|
2014-02-13 |
2019-10-15 |
Takara Bio Usa, Inc. |
Methods of depleting a target molecule from an initial collection of nucleic acids, and compositions and kits for practicing the same
|
KR20160130392A
(ko)
|
2014-02-18 |
2016-11-11 |
듀크 유니버시티 |
바이러스 복제의 불활성화를 위한 조성물 및 그의 제조 및 사용 방법
|
US10370680B2
(en)
|
2014-02-24 |
2019-08-06 |
Sangamo Therapeutics, Inc. |
Method of treating factor IX deficiency using nuclease-mediated targeted integration
|
US11186843B2
(en)
|
2014-02-27 |
2021-11-30 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
CN103820454B
(zh)
*
|
2014-03-04 |
2016-03-30 |
上海金卫生物技术有限公司 |
CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
|
CN111500569A
(zh)
*
|
2014-03-05 |
2020-08-07 |
国立大学法人神户大学 |
特异性转变靶向dna序列的核酸碱基的基因组序列的修饰方法、及其使用的分子复合体
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
UA124375C2
(uk)
|
2014-03-14 |
2021-09-08 |
Кібус Юс Ллс |
Спосіб здійснення спрямованої генетичної зміни днк в клітині рослини з використанням нуклеази crispr і модифікованого gron
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
MA39390B2
(fr)
*
|
2014-03-21 |
2022-04-29 |
Genzyme Corp |
Thérapie génique pour le traitement de la rétinite pigmentaire
|
CN107074927B
(zh)
*
|
2014-03-24 |
2021-04-02 |
艾摩科诊断公司 |
用于全身性和非全身性自身免疫紊乱的改进的抗核抗体检测和诊断
|
US20170173086A1
(en)
*
|
2014-03-25 |
2017-06-22 |
Ginkgo Bioworks, Inc. |
Methods and Genetic Systems for Cell Engineering
|
EP3122880B1
(en)
|
2014-03-26 |
2021-05-05 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
US11318206B2
(en)
|
2014-03-28 |
2022-05-03 |
Aposense Ltd |
Compounds and methods for trans-membrane delivery of molecules
|
EP3125946B1
(en)
*
|
2014-03-28 |
2022-12-07 |
Aposense Ltd. |
Compounds and methods for trans-membrane delivery of molecules
|
WO2015153791A1
(en)
*
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 2 (hsv-2)
|
WO2015153940A1
(en)
*
|
2014-04-03 |
2015-10-08 |
Massachusetts Institute Of Technology |
Methods and compositions for the production of guide rna
|
KR20240042250A
(ko)
|
2014-04-07 |
2024-04-01 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
CN106460003A
(zh)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
用于使用crispr相关基因rna引导阻遏转录的方法和组合物
|
EP3132030B1
(en)
*
|
2014-04-18 |
2020-08-26 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
CA2946309C
(en)
|
2014-04-25 |
2021-11-09 |
Michael MILSOM |
Synthetic bcl11a micrornas for treating hemoglobinopathies
|
WO2015168404A1
(en)
*
|
2014-04-30 |
2015-11-05 |
Massachusetts Institute Of Technology |
Toehold-gated guide rna for programmable cas9 circuitry with rna input
|
WO2015172153A1
(en)
|
2014-05-09 |
2015-11-12 |
Yale University |
Topical formulation of hyperbranched polyglycerol-coated particles thereof
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
WO2015175642A2
(en)
*
|
2014-05-13 |
2015-11-19 |
Sangamo Biosciences, Inc. |
Methods and compositions for prevention or treatment of a disease
|
BR112016026809A2
(pt)
|
2014-05-19 |
2017-12-12 |
Pfizer |
compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
|
EP3152221A4
(en)
*
|
2014-05-20 |
2018-01-24 |
Regents of the University of Minnesota |
Method for editing a genetic sequence
|
WO2015184262A1
(en)
|
2014-05-30 |
2015-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
US9970001B2
(en)
|
2014-06-05 |
2018-05-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for nuclease design
|
LT3152312T
(lt)
*
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Tikslinio lokuso modifikavimo būdai ir kompozicijos
|
WO2015191693A2
(en)
*
|
2014-06-10 |
2015-12-17 |
Massachusetts Institute Of Technology |
Method for gene editing
|
US11274302B2
(en)
*
|
2016-08-17 |
2022-03-15 |
Diacarta Ltd |
Specific synthetic chimeric Xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing CRISPR mediated genome editing efficiency
|
JP6730199B2
(ja)
|
2014-06-11 |
2020-07-29 |
デューク ユニバーシティ |
合成代謝弁を用いた迅速かつ動的なフラックス制御のための組成物及び方法
|
EP3154694A1
(en)
|
2014-06-13 |
2017-04-19 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
EP3157328B1
(en)
*
|
2014-06-17 |
2021-08-04 |
Poseida Therapeutics, Inc. |
A method for directing proteins to specific loci in the genome and uses thereof
|
CN106604994B
(zh)
|
2014-06-23 |
2021-12-14 |
通用医疗公司 |
通过测序评估的DSBs的全基因组无偏鉴定(GUIDE-Seq)
|
PT3155099T
(pt)
|
2014-06-23 |
2018-04-20 |
Regeneron Pharma |
Montagem de dna mediada por nuclease
|
RU2771532C2
(ru)
|
2014-06-26 |
2022-05-05 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленных генетических модификаций и способы их применения
|
WO2016007347A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
WO2016011080A2
(en)
*
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
CA2954920A1
(en)
*
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
JP7113618B2
(ja)
|
2014-07-15 |
2022-08-05 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法用の操作された細胞
|
US20160053272A1
(en)
*
|
2014-07-18 |
2016-02-25 |
Whitehead Institute For Biomedical Research |
Methods Of Modifying A Sequence Using CRISPR
|
US20160053304A1
(en)
*
|
2014-07-18 |
2016-02-25 |
Whitehead Institute For Biomedical Research |
Methods Of Depleting Target Sequences Using CRISPR
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
CN107109419B
(zh)
|
2014-07-21 |
2020-12-22 |
诺华股份有限公司 |
使用cd33嵌合抗原受体治疗癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3172321B2
(en)
*
|
2014-07-21 |
2023-01-04 |
Illumina, Inc. |
Polynucleotide enrichment using crispr-cas systems
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
US20160076093A1
(en)
*
|
2014-08-04 |
2016-03-17 |
University Of Washington |
Multiplex homology-directed repair
|
CN113789317B
(zh)
|
2014-08-06 |
2024-02-23 |
基因工具股份有限公司 |
使用空肠弯曲杆菌crispr/cas系统衍生的rna引导的工程化核酸酶的基因编辑
|
WO2016022866A1
(en)
*
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
US10513711B2
(en)
|
2014-08-13 |
2019-12-24 |
Dupont Us Holding, Llc |
Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
|
WO2016025759A1
(en)
|
2014-08-14 |
2016-02-18 |
Shen Yuelei |
Dna knock-in system
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
US9879270B2
(en)
*
|
2014-08-15 |
2018-01-30 |
Wisconsin Alumni Research Foundation |
Constructs and methods for genome editing and genetic engineering of fungi and protists
|
EP3183367B1
(en)
|
2014-08-19 |
2019-06-26 |
Pacific Biosciences Of California, Inc. |
Compositions and methods for enrichment of nucleic acids
|
US10435685B2
(en)
|
2014-08-19 |
2019-10-08 |
Pacific Biosciences Of California, Inc. |
Compositions and methods for enrichment of nucleic acids
|
EP3183358B1
(en)
*
|
2014-08-19 |
2020-10-07 |
President and Fellows of Harvard College |
Rna-guided systems for probing and mapping of nucleic acids
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
SG11201701245QA
(en)
|
2014-08-27 |
2017-03-30 |
Caribou Biosciences Inc |
Methods for increasing cas9-mediated engineering efficiency
|
EP3633032A3
(en)
*
|
2014-08-28 |
2020-07-29 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
EP3191595B1
(en)
|
2014-09-12 |
2019-12-25 |
E. I. du Pont de Nemours and Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
WO2016049024A2
(en)
*
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
EP3197269A1
(en)
|
2014-09-26 |
2017-08-02 |
Purecircle Usa Inc. |
Single nucleotide polymorphism (snp) markers for stevia
|
WO2016054106A1
(en)
*
|
2014-09-29 |
2016-04-07 |
The Regents Of The University Of California |
SCAFFOLD RNAs
|
JP2017534295A
(ja)
|
2014-09-29 |
2017-11-24 |
ザ ジャクソン ラボラトリー |
エレクトロポレーションによる遺伝子改変哺乳動物の高効率ハイスループット生成
|
SG11201702614SA
(en)
|
2014-10-01 |
2017-04-27 |
Eagle Biolog Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
WO2016050512A1
(en)
|
2014-10-03 |
2016-04-07 |
Bayer Cropscience Nv |
Methods and means for increasing stress tolerance and biomass in plants
|
SG11201702309RA
(en)
|
2014-10-15 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for generating or maintaining pluripotent cells
|
WO2016061523A1
(en)
*
|
2014-10-17 |
2016-04-21 |
Howard Hughes Medical Institute |
Genomic probes
|
WO2016065364A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Life Technologies Corporation |
Compositions and methods for enhancing homologous recombination
|
EP3215168B1
(en)
|
2014-10-31 |
2023-08-02 |
The Trustees of the University of Pennsylvania |
Altering gene expression in modified t cells and uses thereof
|
DK3212789T3
(da)
*
|
2014-10-31 |
2020-07-27 |
Massachusetts Inst Technology |
Massiv parallel kombinatorisk genetik til crispr
|
WO2016073559A1
(en)
*
|
2014-11-05 |
2016-05-12 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
|
CN107406838A
(zh)
*
|
2014-11-06 |
2017-11-28 |
纳幕尔杜邦公司 |
Rna引导的内切核酸酶向细胞中的肽介导的递送
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
WO2016080097A1
(ja)
*
|
2014-11-17 |
2016-05-26 |
国立大学法人東京医科歯科大学 |
簡便で高効率の遺伝子改変非ヒト哺乳動物の作製方法
|
CN104531632A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
快速降解的Cas9-ODC422-461融合蛋白及其应用
|
KR20230070319A
(ko)
|
2014-11-21 |
2023-05-22 |
리제너론 파마슈티칼스 인코포레이티드 |
쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
|
EP3224353B9
(en)
*
|
2014-11-26 |
2023-08-09 |
Technology Innovation Momentum Fund (Israel) Limited Partnership |
Targeted elimination of bacterial genes
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
EP3227446A1
(en)
|
2014-12-01 |
2017-10-11 |
Novartis AG |
Compositions and methods for diagnosis and treatment of prostate cancer
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
JP6830437B2
(ja)
|
2014-12-10 |
2021-02-17 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
疾患を処置するための遺伝子改変された細胞、組織および臓器
|
KR101796518B1
(ko)
*
|
2014-12-12 |
2017-11-14 |
한국한의학연구원 |
일체형 유전자 치료 유도만능줄기세포 제작방법
|
WO2016094845A2
(en)
*
|
2014-12-12 |
2016-06-16 |
Woolf Tod M |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
WO2016094874A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
EA038595B1
(ru)
|
2014-12-16 |
2021-09-21 |
Си3Джей ТЕРАПЬЮТИКС, ИНК. |
Композиции и способы для конструирования вирусного генома in vitro
|
AU2015363113B2
(en)
*
|
2014-12-17 |
2021-03-11 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for efficient gene editing in E. coli using guide RNA/Cas endonuclease systems in combination with circular polynucleotide modification templates
|
WO2016097751A1
(en)
*
|
2014-12-18 |
2016-06-23 |
The University Of Bath |
Method of cas9 mediated genome engineering
|
EP3234133B1
(en)
|
2014-12-18 |
2020-11-11 |
Integrated DNA Technologies, Inc. |
Crispr-based compositions and methods of use
|
BR112017013104A2
(pt)
|
2014-12-19 |
2018-05-15 |
Regeneron Pharma |
métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
|
WO2016100857A1
(en)
|
2014-12-19 |
2016-06-23 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
CN114438169A
(zh)
|
2014-12-20 |
2022-05-06 |
阿克生物公司 |
使用CRISPR/Cas系统蛋白靶向消减、富集、和分割核酸的组合物及方法
|
ES2785329T3
(es)
|
2014-12-23 |
2020-10-06 |
Syngenta Participations Ag |
Métodos y composiciones para identificar y enriquecer células que comprenden modificaciones genómicas específicas para el sitio
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
JP2018500037A
(ja)
*
|
2014-12-31 |
2018-01-11 |
シンセティック ジェノミクス インコーポレーテッド |
高効率なインビボゲノム編集のための組成物及び方法
|
EP3242950B1
(en)
*
|
2015-01-06 |
2021-10-06 |
DSM IP Assets B.V. |
A crispr-cas system for a filamentous fungal host cell
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
MA41349A
(fr)
*
|
2015-01-14 |
2017-11-21 |
Univ Temple |
Éradication de l'herpès simplex de type i et d'autres virus de l'herpès associés guidée par arn
|
US11421241B2
(en)
|
2015-01-27 |
2022-08-23 |
Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences |
Method for conducting site-specific modification on entire plant via gene transient expression
|
US10059940B2
(en)
*
|
2015-01-27 |
2018-08-28 |
Minghong Zhong |
Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
|
BR112017016080B1
(pt)
|
2015-01-28 |
2024-02-20 |
Caribou Biosciences, Inc |
Polinucleotídeo crispr da classe 2 único, sistema crispr da classe 2 e método in vitro de modificação de uma molécula de ácido nucleico alvo em um organismo não-humano, ou em uma célula
|
US11180792B2
(en)
|
2015-01-28 |
2021-11-23 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
CN107429254B
(zh)
*
|
2015-01-30 |
2021-10-15 |
加利福尼亚大学董事会 |
原代造血细胞中的蛋白递送
|
PT3265563T
(pt)
*
|
2015-02-02 |
2021-06-03 |
Meiragtx Uk Ii Ltd |
Regulação da expressão genética por modulação mediada por aptâmero de splicing alternativo
|
CN115029362A
(zh)
|
2015-02-06 |
2022-09-09 |
新加坡国立大学 |
核酸、包含其的工程免疫细胞及其生产方法和用途
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
EP3260539B1
(en)
*
|
2015-02-19 |
2021-10-06 |
Tokushima University |
Method for transferring cas9 mrna into mammalian fertilized egg by electroporation
|
BR112017017812A2
(pt)
|
2015-02-23 |
2018-04-10 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de hemoglobinopatias
|
EP3262173A2
(en)
|
2015-02-23 |
2018-01-03 |
Crispr Therapeutics AG |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
EP3262175A4
(en)
|
2015-02-25 |
2018-10-31 |
Jumpcode Genomics, Inc. |
Methods and compositions for in silico long read sequencing
|
CN107532161A
(zh)
|
2015-03-03 |
2018-01-02 |
通用医疗公司 |
具有改变的PAM特异性的工程化CRISPR‑Cas9核酸酶
|
WO2016142427A1
(en)
|
2015-03-10 |
2016-09-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method ank kit for reprogramming somatic cells
|
WO2016148994A1
(en)
|
2015-03-13 |
2016-09-22 |
The Jackson Laboratory |
A three-component crispr/cas complex system and uses thereof
|
WO2016149422A1
(en)
*
|
2015-03-16 |
2016-09-22 |
The Broad Institute, Inc. |
Encoding of dna vector identity via iterative hybridization detection of a barcode transcript
|
EP3929291A1
(en)
|
2015-03-17 |
2021-12-29 |
Bio-Rad Laboratories, Inc. |
Detection of genome editing
|
CN107532177A
(zh)
|
2015-03-24 |
2018-01-02 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
WO2016154596A1
(en)
*
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
US10450576B2
(en)
|
2015-03-27 |
2019-10-22 |
E I Du Pont De Nemours And Company |
Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
|
KR20180029953A
(ko)
|
2015-03-31 |
2018-03-21 |
엑셀리겐 사이언티픽, 인코포레이티드 |
세포 또는 유기체의 게놈으로의 DNA 서열의 표적화 혼입을 위한 Cas 9 레트로바이러스 인테그라제 시스템 및 Cas 9 재조합효소 시스템
|
EP3280803B1
(en)
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
US11390860B2
(en)
*
|
2015-04-13 |
2022-07-19 |
The University Of Tokyo |
Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
|
US10544424B2
(en)
|
2015-04-15 |
2020-01-28 |
Synthetic Genomics, Inc. |
Algal chloroplastic SRP54 mutants
|
US11674144B2
(en)
*
|
2015-04-16 |
2023-06-13 |
California Institute Of Technology |
Fractional regulation of transcription
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Cas9分子/ガイドrna分子複合体の評価
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
US11845928B2
(en)
*
|
2015-05-04 |
2023-12-19 |
Tsinghua University |
Methods and kits for fragmenting DNA
|
EP3461337A1
(en)
|
2015-05-06 |
2019-04-03 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
WO2016182917A1
(en)
*
|
2015-05-08 |
2016-11-17 |
Children's Medical Center Corporation |
Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
WO2016183402A2
(en)
*
|
2015-05-13 |
2016-11-17 |
President And Fellows Of Harvard College |
Methods of making and using guide rna for use with cas9 systems
|
EP3294879A4
(en)
*
|
2015-05-14 |
2019-02-20 |
University of Southern California |
OPTIMIZED GENETIZATION WITH A RECOMBINANT ENDONUCLEASE SYSTEM
|
US20180142236A1
(en)
*
|
2015-05-15 |
2018-05-24 |
Ge Healthcare Dharmacon, Inc. |
Synthetic single guide rna for cas9-mediated gene editing
|
CN107709562A
(zh)
*
|
2015-05-15 |
2018-02-16 |
先锋国际良种公司 |
指导rna/cas内切核酸酶系统
|
EP3095870A1
(en)
|
2015-05-19 |
2016-11-23 |
Kws Saat Se |
Methods for the in planta transformation of plants and manufacturing processes and products based and obtainable therefrom
|
EP3303607A4
(en)
|
2015-05-29 |
2018-10-10 |
North Carolina State University |
Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
US10883103B2
(en)
|
2015-06-02 |
2021-01-05 |
Monsanto Technology Llc |
Compositions and methods for delivery of a polynucleotide into a plant
|
CN108368502B
(zh)
*
|
2015-06-03 |
2022-03-18 |
内布拉斯加大学董事委员会 |
使用单链dna的dna编辑
|
US10392607B2
(en)
|
2015-06-03 |
2019-08-27 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
WO2016193945A2
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
CN108026526B
(zh)
|
2015-06-09 |
2023-05-12 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
US20160362667A1
(en)
|
2015-06-10 |
2016-12-15 |
Caribou Biosciences, Inc. |
CRISPR-Cas Compositions and Methods
|
CA2985714C
(en)
|
2015-06-12 |
2024-02-06 |
Lonza Walkersville, Inc. |
Methods for nuclear reprogramming using synthetic transcription factors
|
GB201510296D0
(en)
*
|
2015-06-12 |
2015-07-29 |
Univ Wageningen |
Thermostable CAS9 nucleases
|
CA2983874C
(en)
|
2015-06-15 |
2022-06-21 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
DK3310909T3
(da)
*
|
2015-06-17 |
2021-09-13 |
Poseida Therapeutics Inc |
Sammensætninger og fremgangsmåder til at føre proteiner til specifikke loci i genomet
|
EP3310932B1
(en)
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
CN108026545A
(zh)
|
2015-06-17 |
2018-05-11 |
Uab研究基金会 |
用于将功能性多肽引入到血细胞谱系细胞中的crispr/cas9复合物
|
WO2016205613A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzyme mutations reducing off-target effects
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
WO2016205749A1
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2017004279A2
(en)
*
|
2015-06-29 |
2017-01-05 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
JP6765665B2
(ja)
*
|
2015-07-13 |
2020-10-07 |
国立研究開発法人農業・食品産業技術総合研究機構 |
不稔化植物、不稔化植物の作出方法、及びベクター
|
CA2992580C
(en)
|
2015-07-15 |
2022-09-20 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
WO2017015101A1
(en)
*
|
2015-07-17 |
2017-01-26 |
University Of Washington |
Methods for maximizing the efficiency of targeted gene correction
|
EP3325018A4
(en)
|
2015-07-22 |
2019-04-24 |
Duke University |
HIGH EFFICIENCY SCREENING OF REGULATORY ELEMENT FUNCTION USING EPIGENOUS EDITING TECHNOLOGIES
|
CN108472314A
(zh)
|
2015-07-31 |
2018-08-31 |
明尼苏达大学董事会 |
修饰的细胞和治疗方法
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
CA2995036A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
B형 간염 바이러스 감염에 대한 rnai 치료법
|
JP2018529759A
(ja)
|
2015-08-14 |
2018-10-11 |
ザ ユニバーシティー オブ シドニー |
治療用コネキシン45阻害剤
|
KR102127418B1
(ko)
|
2015-08-14 |
2020-06-26 |
인스티튜트 오브 제네틱스 앤드 디벨롭멘털 바이오롤지, 차이니즈 아카데미 오브 사이언시스 |
부위-특이적인 뉴클레오티드 치환을 통해 글리포세이트-내성 벼를 수득하는 방법
|
CA2995582A1
(en)
|
2015-08-19 |
2017-02-23 |
Children's Research Institute, Children's National Medical Center |
Compositions and methods for treating graft versus host disease
|
CN108138176B
(zh)
|
2015-08-19 |
2022-05-24 |
阿克生物公司 |
使用基于核酸引导的核酸酶的系统捕获核酸
|
JP6905755B2
(ja)
|
2015-08-25 |
2021-07-21 |
デューク ユニバーシティ |
Rnaガイド型エンドヌクレアーゼを使用してゲノム工学における特異性を改善する組成物および方法
|
DK3341483T3
(da)
|
2015-08-28 |
2020-03-16 |
Pioneer Hi Bred Int |
Ochrobactrum-medieret transformation af planter
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
EP3341477B1
(en)
|
2015-08-28 |
2022-03-23 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
WO2017040511A1
(en)
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
WO2017040709A1
(en)
|
2015-08-31 |
2017-03-09 |
Caribou Biosciences, Inc. |
Directed nucleic acid repair
|
CA3036409C
(en)
*
|
2015-09-08 |
2023-07-11 |
Erik J. Sontheimer |
Dnase h activity of neisseria meningitidis cas9
|
CN108271384B
(zh)
*
|
2015-09-09 |
2022-04-15 |
国立大学法人神户大学 |
用于特异性转变靶向dna序列的核酸碱基的革兰氏阳性菌的基因组序列的转变方法、及其使用的分子复合体
|
AU2016321333A1
(en)
*
|
2015-09-09 |
2018-04-26 |
Psomagen, Inc. |
Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
|
CA3005985A1
(en)
*
|
2015-09-09 |
2017-03-16 |
uBiome, Inc. |
Method and system for microbiome-derived diagnostics and therapeutics of infectious disease and other health conditions associated with antibiotic usage
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
JP2018530536A
(ja)
|
2015-09-11 |
2018-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
ヌクレアーゼDSBの完全照合およびシーケンシング(FIND−seq)
|
CN116640316A
(zh)
|
2015-09-14 |
2023-08-25 |
得克萨斯州大学系统董事会 |
亲脂阳离子树枝状聚合物及其用途
|
EP3352795B1
(en)
*
|
2015-09-21 |
2020-08-12 |
The Regents of The University of California |
Compositions and methods for target nucleic acid modification
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
EP3356533A1
(en)
*
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
US20170088828A1
(en)
*
|
2015-09-29 |
2017-03-30 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
EP3356520B1
(en)
|
2015-10-02 |
2022-03-23 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
WO2017062855A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Monsanto Technology Llc |
Novel rna-guided nucleases and uses thereof
|
DK3362560T3
(da)
|
2015-10-12 |
2022-11-07 |
Dupont Us Holding Llc |
Beskyttede dna-templater til genmodificering og forøget homolog rekombination i celler og fremgangsmåder til anvendelse
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
US9862941B2
(en)
|
2015-10-14 |
2018-01-09 |
Pioneer Hi-Bred International, Inc. |
Single cell microfluidic device
|
FR3042506B1
(fr)
*
|
2015-10-16 |
2018-11-30 |
IFP Energies Nouvelles |
Outil genetique de transformation de bacteries clostridium
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
AU2016341041A1
(en)
|
2015-10-20 |
2018-03-15 |
Pioneer Hi-Bred International, Inc. |
Methods and compositions for marker-free genome modification
|
JP7059179B2
(ja)
*
|
2015-10-20 |
2022-04-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
遺伝子操作のための方法及び製品
|
CN109153980B
(zh)
*
|
2015-10-22 |
2023-04-14 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
WO2017068120A1
(en)
|
2015-10-22 |
2017-04-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Endonuclease-barcoding
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and their uses
|
US9677090B2
(en)
|
2015-10-23 |
2017-06-13 |
Caribou Biosciences, Inc. |
Engineered nucleic-acid targeting nucleic acids
|
EP3368063B1
(en)
|
2015-10-28 |
2023-09-06 |
Vertex Pharmaceuticals Inc. |
Materials and methods for treatment of duchenne muscular dystrophy
|
WO2017079406A1
(en)
|
2015-11-03 |
2017-05-11 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
WO2017077394A2
(en)
|
2015-11-04 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
BR112018007796A2
(pt)
|
2015-11-06 |
2018-10-30 |
Du Pont |
plantas de soja, partes de plantas de soja ou sementes de soja, método para selecionar uma célula de soja, métodos de seleção de uma célula de soja e de produção de um locus e molécula de ácido nucleico
|
EP3370513A1
(en)
|
2015-11-06 |
2018-09-12 |
The Jackson Laboratory |
Large genomic dna knock-in and uses thereof
|
US11866727B2
(en)
|
2015-11-06 |
2024-01-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1A
|
WO2017081288A1
(en)
|
2015-11-11 |
2017-05-18 |
Lonza Ltd |
Crispr-associated (cas) proteins with reduced immunogenicity
|
CA2947904A1
(en)
*
|
2015-11-12 |
2017-05-12 |
Pfizer Inc. |
Tissue-specific genome engineering using crispr-cas9
|
WO2017083766A1
(en)
*
|
2015-11-13 |
2017-05-18 |
Massachusetts Institute Of Technology |
High-throughput crispr-based library screening
|
EP3377042A4
(en)
|
2015-11-16 |
2019-05-29 |
The Research Institute at Nationwide Children's Hospital |
SUBSTANCES AND METHODS FOR THE TREATMENT OF MYOPATHIES BASED ON TITINE AND OTHER TITINOPATHIES
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
US11220693B2
(en)
|
2015-11-27 |
2022-01-11 |
National University Corporation Kobe University |
Method for converting monocot plant genome sequence in which nucleic acid base in targeted DNA sequence is specifically converted, and molecular complex used therein
|
US10086024B2
(en)
|
2015-11-30 |
2018-10-02 |
Joseph E. Kovarik |
Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
|
US10568916B2
(en)
|
2015-11-30 |
2020-02-25 |
Joseph E. Kovarik |
Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
|
US10675347B2
(en)
|
2015-11-30 |
2020-06-09 |
Joseph E. Kovarik |
Method and system for protecting honey bees from fipronil pesticides
|
US10933128B2
(en)
|
2015-11-30 |
2021-03-02 |
Joseph E. Kovarik |
Method and system for protecting honey bees from pesticides
|
US11529412B2
(en)
|
2015-11-30 |
2022-12-20 |
Seed Health, Inc. |
Method and system for protecting honey bees from pesticides
|
US11903974B2
(en)
|
2015-11-30 |
2024-02-20 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
US11851653B2
(en)
|
2015-12-01 |
2023-12-26 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
US10946042B2
(en)
|
2015-12-01 |
2021-03-16 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for selective phagocytosis of human cancer cells
|
KR102093570B1
(ko)
*
|
2015-12-04 |
2020-03-25 |
카리부 바이오사이언시스 인코포레이티드 |
조작된 핵산 표적화 핵산
|
DK3386550T3
(da)
|
2015-12-07 |
2021-04-26 |
Arc Bio Llc |
Fremgangsmåder til fremstilling og anvendelse af guide nukleinsyrer
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
KR20180084756A
(ko)
|
2015-12-07 |
2018-07-25 |
지머젠 인코포레이티드 |
코리네박테리움 글루타미컴으로부터의 프로모터
|
US20180362961A1
(en)
|
2015-12-11 |
2018-12-20 |
Danisco Us Inc. |
Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
|
EP3392337B1
(en)
*
|
2015-12-18 |
2024-03-06 |
Japan Science and Technology Agency |
Genetic modification non-human organism, egg cells, fertilized eggs, and method for modifying target genes
|
EP3390632A1
(en)
*
|
2015-12-18 |
2018-10-24 |
Danisco US Inc. |
Methods and compositions for polymerase ii (pol-ii) based guide rna expression
|
WO2017106767A1
(en)
*
|
2015-12-18 |
2017-06-22 |
The Scripps Research Institute |
Production of unnatural nucleotides using a crispr/cas9 system
|
WO2017105991A1
(en)
|
2015-12-18 |
2017-06-22 |
Danisco Us Inc. |
Methods and compositions for t-rna based guide rna expression
|
EP3390624A4
(en)
|
2015-12-18 |
2019-07-10 |
The Regents of The University of California |
MODIFIED POLYPEPTIDES AND METHOD OF USE THEREOF
|
SG10201913163PA
(en)
|
2015-12-18 |
2020-03-30 |
Oncosec Medical Inc |
Plasmid constructs for heterologous protein expression and methods of use
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
CN109312339B
(zh)
|
2015-12-23 |
2022-01-28 |
克里斯珀医疗股份公司 |
用于治疗肌萎缩侧索硬化症和/或额颞叶变性的材料和方法
|
US11026969B2
(en)
|
2015-12-23 |
2021-06-08 |
Fred Hutchinson Cancer Research Center |
High affinity T cell receptors and uses thereof
|
ES2944597T3
(es)
|
2015-12-30 |
2023-06-22 |
Novartis Ag |
Terapias con células efectoras inmunitarias de eficacia mejorada
|
IL260532B2
(en)
|
2016-01-11 |
2023-12-01 |
Univ Leland Stanford Junior |
Systems containing chaperone proteins and their uses for controlling gene expression
|
US11441146B2
(en)
|
2016-01-11 |
2022-09-13 |
Christiana Care Health Services, Inc. |
Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
|
SG10202112024PA
(en)
*
|
2016-01-11 |
2021-12-30 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of immunotherapy
|
US11427837B2
(en)
*
|
2016-01-12 |
2022-08-30 |
The Regents Of The University Of California |
Compositions and methods for enhanced genome editing
|
WO2017124086A1
(en)
|
2016-01-15 |
2017-07-20 |
The Jackson Laboratory |
Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein
|
BR112018015348A2
(pt)
|
2016-01-26 |
2018-12-18 |
Pioneer Hi Bred Int |
método para obter uma planta de milho ceroso, planta, semente, polinucleotídeo-guia e método para produzir uma planta híbrida de milho ceroso
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
CA3013179A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Bonac Corporation |
Artificial single guide rna and use thereof
|
EP3411078A1
(en)
|
2016-02-02 |
2018-12-12 |
Crispr Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017136794A1
(en)
|
2016-02-03 |
2017-08-10 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
KR20180116769A
(ko)
|
2016-02-09 |
2018-10-25 |
시버스 유에스 엘엘씨 |
올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
|
CN109072205A
(zh)
*
|
2016-02-10 |
2018-12-21 |
密歇根大学董事会 |
核酸的检测
|
US11339427B2
(en)
|
2016-02-12 |
2022-05-24 |
Jumpcode Genomics, Inc. |
Method for target specific RNA transcription of DNA sequences
|
US10876129B2
(en)
|
2016-02-12 |
2020-12-29 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
US9896696B2
(en)
|
2016-02-15 |
2018-02-20 |
Benson Hill Biosystems, Inc. |
Compositions and methods for modifying genomes
|
JP2019508037A
(ja)
|
2016-02-16 |
2019-03-28 |
イェール ユニバーシティーYale Universit |
標的化遺伝子編集を増強するための組成物およびその使用方法
|
WO2017143061A1
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
EP3417061B1
(en)
|
2016-02-18 |
2022-10-26 |
The Regents of the University of California |
Methods and compositions for gene editing in stem cells
|
DK3653709T3
(da)
|
2016-02-22 |
2021-03-08 |
Caribou Biosciences Inc |
Fremgangsmåder til modulering af dna-reparationsresultater
|
CN105646719B
(zh)
*
|
2016-02-24 |
2019-12-20 |
无锡市妇幼保健院 |
一种高效定点转基因的工具及其应用
|
US11530253B2
(en)
|
2016-02-25 |
2022-12-20 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
|
SG11201807025SA
(en)
*
|
2016-02-26 |
2018-09-27 |
Lanzatech New Zealand Ltd |
Crispr/cas systems for c-1 fixing bacteria
|
WO2017151444A1
(en)
|
2016-02-29 |
2017-09-08 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
|
EP3426780A1
(en)
|
2016-03-11 |
2019-01-16 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
CA3010628A1
(en)
|
2016-03-11 |
2017-09-14 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
WO2017155715A1
(en)
|
2016-03-11 |
2017-09-14 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 systems and methods of use
|
CN109152848B
(zh)
*
|
2016-03-15 |
2022-12-09 |
马萨诸塞大学 |
抗-crispr化合物以及使用方法
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
US20190117799A1
(en)
|
2016-04-01 |
2019-04-25 |
The Brigham And Women's Hospital, Inc. |
Stimuli-responsive nanoparticles for biomedical applications
|
EP3443086B1
(en)
|
2016-04-13 |
2021-11-24 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
WO2017180915A2
(en)
*
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
SG11201808920RA
(en)
*
|
2016-04-14 |
2018-11-29 |
Boco Silicon Valley Inc |
Genome editing of human neural stem cells using nucleases
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
JP7058223B2
(ja)
|
2016-04-15 |
2022-04-21 |
メモリアル スローン ケタリング キャンサー センター |
トランスジェニックt細胞及びキメラ抗原受容体t細胞組成物及び関連方法
|
WO2017181107A2
(en)
*
|
2016-04-16 |
2017-10-19 |
Ohio State Innovation Foundation |
Modified cpf1 mrna, modified guide rna, and uses thereof
|
FI3445388T3
(fi)
|
2016-04-18 |
2024-05-15 |
Vertex Pharma |
Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
|
CN109414450A
(zh)
*
|
2016-04-22 |
2019-03-01 |
因特利亚治疗公司 |
用于治疗与转录因子4中三核苷酸重复相关的疾病的组合物和方法
|
CA3210120C
(en)
|
2016-04-25 |
2024-04-09 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
EP3448996A1
(en)
|
2016-04-26 |
2019-03-06 |
Massachusetts Institute of Technology |
Extensible recombinase cascades
|
US11410746B2
(en)
|
2016-04-27 |
2022-08-09 |
Massachusetts Institute Of Technology |
Stable nanoscale nucleic acid assemblies and methods thereof
|
WO2017189914A1
(en)
|
2016-04-27 |
2017-11-02 |
Massachusetts Institute Of Technology |
Sequence-controlled polymer random access memory storage
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017193053A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Woolf Tod M |
Improved methods for genome editing with and without programmable nucleases
|
EP3452094B1
(en)
|
2016-05-06 |
2021-11-17 |
The Brigham and Women's Hospital, Inc. |
Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
|
WO2017197128A1
(en)
|
2016-05-11 |
2017-11-16 |
Yale University |
Poly(amine-co-ester) nanoparticles and methods of use thereof
|
JP2017205104A
(ja)
*
|
2016-05-13 |
2017-11-24 |
株式会社カネカ |
植物のゲノム編集方法
|
US11499158B2
(en)
|
2016-05-13 |
2022-11-15 |
Kaneka Corporation |
Method for modifying plant
|
JP6967217B2
(ja)
|
2016-05-13 |
2021-11-17 |
株式会社カネカ |
形質転換植物の作製方法
|
WO2017201476A1
(en)
|
2016-05-20 |
2017-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
WO2017205846A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Aadigen, Llc |
Peptides and nanoparticles for intracellular delivery of genome-editing molecules
|
US11286493B2
(en)
|
2016-05-27 |
2022-03-29 |
The Regents Of The University Of California |
Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci
|
AU2017274145B2
(en)
*
|
2016-06-02 |
2020-07-23 |
Sigma-Aldrich Co Llc |
Using programmable DNA binding proteins to enhance targeted genome modification
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
US11779657B2
(en)
|
2016-06-10 |
2023-10-10 |
City Of Hope |
Compositions and methods for mitochondrial genome editing
|
BR112018076027A2
(pt)
|
2016-06-14 |
2019-03-26 |
Pioneer Hi-Bred International, Inc. |
método para modificar uma sequência-alvo no genoma de uma célula vegetal; método para editar uma sequência de nucleotídeos no genoma de uma célula vegetal; método para modificar simultaneamente múltiplas sequências-alvo no genoma de uma célula vegetal; método para modificar uma sequênciaalvo de dna no genoma de uma célula vegetal e modelo de modificação de polinucleotídeo
|
WO2017217768A1
(ko)
*
|
2016-06-15 |
2017-12-21 |
주식회사 툴젠 |
온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도
|
US10337051B2
(en)
|
2016-06-16 |
2019-07-02 |
The Regents Of The University Of California |
Methods and compositions for detecting a target RNA
|
US11788083B2
(en)
*
|
2016-06-17 |
2023-10-17 |
The Broad Institute, Inc. |
Type VI CRISPR orthologs and systems
|
WO2017222773A1
(en)
|
2016-06-20 |
2017-12-28 |
Pioneer Hi-Bred International, Inc. |
Novel cas systems and methods of use
|
US11293021B1
(en)
|
2016-06-23 |
2022-04-05 |
Inscripta, Inc. |
Automated cell processing methods, modules, instruments, and systems
|
EP3474669B1
(en)
|
2016-06-24 |
2022-04-06 |
The Regents of The University of Colorado, A Body Corporate |
Methods for generating barcoded combinatorial libraries
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
WO2018005589A1
(en)
|
2016-06-28 |
2018-01-04 |
Cellectis |
Altering expression of gene products in plants through targeted insertion of nucleic acid sequences
|
CA3029119A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
WO2018002762A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
EP3478829A1
(en)
|
2016-06-29 |
2019-05-08 |
Crispr Therapeutics AG |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
EP3478845A4
(en)
|
2016-06-30 |
2019-07-31 |
Zymergen, Inc. |
METHODS OF PRODUCING A GLUCOSE PERMEASE BANK AND USES THEREOF
|
JP2019519242A
(ja)
|
2016-06-30 |
2019-07-11 |
ザイマージェン インコーポレイテッド |
細菌ヘモグロビンライブラリーを生成するための方法およびその使用
|
AU2017292169B2
(en)
|
2016-07-06 |
2021-12-23 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of pain related disorders
|
EP3481857A1
(en)
|
2016-07-06 |
2019-05-15 |
Crispr Therapeutics AG |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
US11674158B2
(en)
|
2016-07-15 |
2023-06-13 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
WO2018015444A1
(en)
|
2016-07-22 |
2018-01-25 |
Novozymes A/S |
Crispr-cas9 genome editing with multiple guide rnas in filamentous fungi
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
CN106191043B
(zh)
*
|
2016-07-26 |
2019-07-02 |
吉林大学 |
一种基因片段、载体pPlasmid-Clearance及应用
|
AU2017302611B2
(en)
|
2016-07-28 |
2021-12-09 |
Regeneron Pharmaceuticals, Inc. |
GPR156 variants and uses thereof
|
WO2018023014A1
(en)
|
2016-07-29 |
2018-02-01 |
Regeneron Pharmaceuticals, Inc. |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
EP3494220A1
(en)
|
2016-08-02 |
2019-06-12 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
SG11201900907YA
(en)
|
2016-08-03 |
2019-02-27 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
KR101710026B1
(ko)
|
2016-08-10 |
2017-02-27 |
주식회사 무진메디 |
Cas9 단백질 및 가이드 RNA의 혼성체를 함유하는 나노 리포좀 전달체 조성물
|
WO2018031950A1
(en)
|
2016-08-12 |
2018-02-15 |
Caribou Biosciences, Inc. |
Protein engineering methods
|
WO2018035062A1
(en)
*
|
2016-08-16 |
2018-02-22 |
The Regents Of The University Of California |
Method for finding low abundance sequences by hybridization (flash)
|
JP7308143B2
(ja)
*
|
2016-08-19 |
2023-07-13 |
ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ |
Dnaメチル化の編集方法
|
CA3034101A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Bluebird Bio, Inc. |
Genome editing enhancers
|
US20190185850A1
(en)
*
|
2016-08-20 |
2019-06-20 |
Avellino Lab Usa, Inc. |
Single guide rna/crispr/cas9 systems, and methods of use thereof
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
WO2018044920A1
(en)
|
2016-08-29 |
2018-03-08 |
The Regents Of The University Of California |
Topical formulations based on ionic species for skin treatment
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
CN106399311A
(zh)
*
|
2016-09-07 |
2017-02-15 |
同济大学 |
用于Chip‑seq全基因组结合谱的内源蛋白标记的方法
|
EP3510407A1
(en)
|
2016-09-08 |
2019-07-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating nephrotic syndrome
|
EP3510151A4
(en)
|
2016-09-09 |
2020-04-15 |
The Board of Trustees of the Leland Stanford Junior University |
HIGH-THROUGHPUT PRECISION GENE EDITING
|
JP7063885B2
(ja)
|
2016-09-13 |
2022-05-09 |
ザ ジャクソン ラボラトリー |
標的にされた増大するdna脱メチル化
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
JP6866475B2
(ja)
|
2016-09-23 |
2021-04-28 |
フレッド ハッチンソン キャンサー リサーチ センター |
マイナー組織適合性(h)抗原ha−1に特異的なtcr及びその使用
|
CN109844126A
(zh)
|
2016-09-28 |
2019-06-04 |
诺华股份有限公司 |
基于多孔膜的大分子递送系统
|
JP6829761B2
(ja)
*
|
2016-09-29 |
2021-02-10 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
遺伝子編集モジュールおよび遺伝子送達アプローチを解析および最適化するための方法
|
GB201616590D0
(en)
|
2016-09-29 |
2016-11-16 |
Oxford Nanopore Technologies Limited |
Method
|
AU2017335890B2
(en)
|
2016-09-30 |
2024-05-09 |
The Regents Of The University Of California |
RNA-guided nucleic acid modifying enzymes and methods of use thereof
|
EA201990860A1
(ru)
|
2016-09-30 |
2019-10-31 |
|
Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
CN117866991A
(zh)
|
2016-10-07 |
2024-04-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
WO2018069232A1
(en)
|
2016-10-10 |
2018-04-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of having cardiac hypertrophy
|
WO2018071448A1
(en)
|
2016-10-11 |
2018-04-19 |
The Regents Of The University Of California |
Systems and methods to encapsulate and preserve organic matter for analysis
|
US20220275392A1
(en)
|
2016-10-13 |
2022-09-01 |
Pioneer Hi-Bred International, Inc. |
Generating northern leaf blight resistant maize
|
GB2573062A
(en)
|
2016-10-14 |
2019-10-23 |
Harvard College |
AAV delivery of nucleobase editors
|
AU2017341926B2
(en)
|
2016-10-14 |
2022-06-30 |
The General Hospital Corporation |
Epigenetically regulated site-specific nucleases
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
WO2018081138A1
(en)
|
2016-10-24 |
2018-05-03 |
Yale University |
Biodegradable contraceptive implants
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
WO2018080573A1
(en)
|
2016-10-28 |
2018-05-03 |
Massachusetts Institute Of Technology |
Crispr/cas global regulator screening platform
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
WO2018085414A1
(en)
*
|
2016-11-02 |
2018-05-11 |
President And Fellows Of Harvard College |
Engineered guide rna sequences for in situ detection and sequencing
|
WO2018081978A1
(zh)
*
|
2016-11-03 |
2018-05-11 |
深圳华大基因研究院 |
提高基因编辑效率的方法和系统
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
AU2017355507B2
(en)
|
2016-11-04 |
2023-09-21 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
WO2018087391A1
(en)
|
2016-11-14 |
2018-05-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
|
WO2018094356A2
(en)
*
|
2016-11-18 |
2018-05-24 |
Genedit Inc. |
Compositions and methods for target nucleic acid modification
|
KR20190085528A
(ko)
|
2016-11-22 |
2019-07-18 |
싱가포르국립대학교 |
T 세포 악성종양의 면역요법을 위한 키메라 항원 수용체 및 cd7 발현의 차단
|
EP3545090A1
(en)
|
2016-11-28 |
2019-10-02 |
The Board of Regents of The University of Texas System |
Prevention of muscular dystrophy by crispr/cpf1-mediated gene editing
|
EP3548894B1
(en)
|
2016-12-02 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for diagnosing renal cell carcinoma
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
US20190364862A1
(en)
|
2016-12-08 |
2019-12-05 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duchenne muscular dystrophy mutations
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
CN110582302A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和/或蛋白有效负载递送的组合物和方法
|
BR112019012155A2
(pt)
*
|
2016-12-14 |
2019-11-12 |
Stichting Technische Wetenschappen |
uso de pelo menos uma molécula-guia de rna e uma proteína cas, método de ligação, clivagem, marcação ou modificação de um polinucleotídeo alvo de fita dupla, célula transformada, e, complexo de nucleoproteína
|
WO2018112470A1
(en)
|
2016-12-16 |
2018-06-21 |
The Brigham And Women's Hospital, Inc. |
Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
|
WO2018118585A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Agenovir Corporation |
Antiviral compositions
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
WO2018126087A1
(en)
|
2016-12-29 |
2018-07-05 |
Applied Stemcell, Inc. |
Gene editing method using virus
|
EP3342868B1
(en)
|
2016-12-30 |
2019-12-25 |
Systasy Bioscience GmbH |
Constructs and screening methods
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
US20190330658A1
(en)
|
2017-01-05 |
2019-10-31 |
Rutgers, The State University |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
ES2949801T3
(es)
|
2017-01-09 |
2023-10-03 |
Whitehead Inst Biomedical Res |
Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores
|
KR20190104392A
(ko)
|
2017-01-09 |
2019-09-09 |
아포센스 엘티디. |
분자의 막투과 전달을 위한 화합물 및 방법
|
AU2018208463A1
(en)
|
2017-01-10 |
2019-08-01 |
Christina Care Gene Editing Institute, Inc. |
Methods for in vitro site-directed mutagenesis using gene editing technologies
|
EP3569708A4
(en)
*
|
2017-01-13 |
2020-09-09 |
Jichi Medical University |
AAV VECTOR TO DISCONNECT THE COOLAGE RELATED FACTOR ON THE LIVER GENOME
|
CA3047416A1
(en)
|
2017-01-20 |
2018-07-26 |
The Regents Of The University Of California |
Targeted gene activation in plants
|
WO2018136702A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
AU2018213044A1
(en)
|
2017-01-26 |
2019-07-11 |
The Regents Of The University Of California |
Targeted gene demethylation in plants
|
WO2018140899A1
(en)
|
2017-01-28 |
2018-08-02 |
Inari Agriculture, Inc. |
Novel plant cells, plants, and seeds
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
EP3577227A4
(en)
|
2017-02-02 |
2020-12-30 |
Cargill Inc. |
GENETICALLY MODIFIED CELLS PRODUCING C6-C10 FATTY ACID DERIVATIVES
|
JP2020513790A
(ja)
|
2017-02-06 |
2020-05-21 |
ザイマージェン インコーポレイテッド |
発酵によりチラミンを生成させるための遺伝子操作型生合成経路
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
CA3053006C
(en)
|
2017-02-08 |
2023-09-05 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
KR20190116282A
(ko)
|
2017-02-10 |
2019-10-14 |
지머젠 인코포레이티드 |
복수의 숙주를 위한 다중 dna 구조체의 조립 및 편집을 위한 모듈식 범용 플라스미드 디자인 전략
|
IL305141A
(en)
|
2017-02-21 |
2023-10-01 |
Univ Duke |
Preparations and methods for robust dynamic metabolic control
|
US20200040061A1
(en)
|
2017-02-22 |
2020-02-06 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
EP3585900B1
(en)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
CN110662838B
(zh)
|
2017-02-22 |
2024-05-28 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
JP7386082B2
(ja)
|
2017-02-28 |
2023-11-24 |
ブイオーアール バイオファーマ インコーポレーテッド |
系統特異的タンパク質の阻害のための組成物および方法
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
WO2018165629A1
(en)
|
2017-03-10 |
2018-09-13 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
US11332727B2
(en)
*
|
2017-03-14 |
2022-05-17 |
The Regents Of The University Of California |
Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector
|
US20200087403A1
(en)
|
2017-03-15 |
2020-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for the treatment of thrombosis in patients suffering from a myeloproliferative neoplasm
|
EA201992131A1
(ru)
|
2017-03-15 |
2020-02-06 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Высокоаффинные специфичные к mage-a1 tcr и их применение
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
US10980779B2
(en)
|
2017-03-24 |
2021-04-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
GFI1 inhibitors for the treatment of hyperglycemia
|
WO2018172508A1
(en)
|
2017-03-24 |
2018-09-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
CN110914433A
(zh)
*
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
CA3084252A1
(en)
|
2017-03-28 |
2018-10-04 |
Caribou Biosciences, Inc. |
Crispr-associated (cas) protein
|
WO2018178237A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of mitochondrial genetic diseases
|
CA3056650A1
(en)
|
2017-03-30 |
2018-10-04 |
Pioneer Hi-Bred International, Inc. |
Methods of identifying and characterizing gene editing variations in nucleic acids
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
RU2019135845A
(ru)
|
2017-04-11 |
2021-05-11 |
Ридженерон Фармасьютикалз, Инк. |
Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b)
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
US11834670B2
(en)
*
|
2017-04-19 |
2023-12-05 |
Global Life Sciences Solutions Usa Llc |
Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences
|
BR112019021719A2
(pt)
|
2017-04-21 |
2020-06-16 |
The General Hospital Corporation |
Variantes de cpf1 (cas12a) com especificidade para pam alterada
|
DK3612174T3
(da)
|
2017-04-21 |
2023-05-08 |
Inst Nat Sante Rech Med |
Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion
|
CN110799205A
(zh)
|
2017-04-21 |
2020-02-14 |
通用医疗公司 |
利用CRISPR-Cpf1的可诱导、可调和多重的人类基因调节
|
BR112019022201A2
(pt)
|
2017-04-24 |
2020-05-12 |
Dupont Nutrition Biosciences Aps |
Métodos para modular a atividade de uma endonuclease cas, para aumentar a especificidade de uma endonuclease cas e complexo polinucleotídico guia, para aumentar a frequência de recombinação homóloga e para ativação ou repressão gênica, célula e célula vegetal
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
CN110997705A
(zh)
|
2017-05-05 |
2020-04-10 |
巴塞罗那自治大学 |
纳米结构蛋白及其用途
|
WO2018208067A1
(ko)
*
|
2017-05-08 |
2018-11-15 |
주식회사 툴젠 |
인위적으로 조작된 조작면역세포
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
IL270415B1
(en)
|
2017-05-12 |
2024-04-01 |
Crispr Therapeutics Ag |
Materials and methods for cell engineering and their uses in immuno-oncology
|
US11692184B2
(en)
|
2017-05-16 |
2023-07-04 |
The Regents Of The University Of California |
Thermostable RNA-guided endonucleases and methods of use thereof
|
WO2018212361A1
(en)
*
|
2017-05-17 |
2018-11-22 |
Edigene Corporation |
Method of treating diseases associated with myd88 pathways using crispr-gndm system
|
US20200171022A1
(en)
|
2017-05-17 |
2020-06-04 |
Inserm (Institut National De La Santé Et Da La Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
EP3630198A4
(en)
|
2017-05-25 |
2021-04-21 |
The General Hospital Corporation |
USE OF CLIVED DESAMINASES TO LIMIT UNWANTED OUT-OF-TARGET DESAMINATION FROM BASE EDITING
|
WO2018218135A1
(en)
|
2017-05-25 |
2018-11-29 |
The Children's Medical Center Corporation |
Bcl11a guide delivery
|
MX2019014661A
(es)
|
2017-06-05 |
2020-07-29 |
Regeneron Pharma |
Variantes de b4galt1 y usos de estas.
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
WO2018226900A2
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving fungal strains
|
JP2020524490A
(ja)
|
2017-06-06 |
2020-08-20 |
ザイマージェン インコーポレイテッド |
Escherichia Coliを改良するためのHTPゲノム操作プラットフォーム
|
EP3634582A1
(en)
|
2017-06-08 |
2020-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating hyperpigmentation disorders
|
US10780438B2
(en)
|
2017-06-09 |
2020-09-22 |
The Regents Of The University Of California |
High-efficiency encapsulation in droplets based on hydrodynamic vortices control
|
US11517901B2
(en)
|
2017-06-09 |
2022-12-06 |
The Regents Of The University Of California |
High-efficiency particle encapsulation in droplets with particle spacing and downstream droplet sorting
|
EP3635104A1
(en)
|
2017-06-09 |
2020-04-15 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
AU2018285860A1
(en)
|
2017-06-13 |
2020-01-02 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
JP7275054B2
(ja)
|
2017-06-15 |
2023-05-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
標的化された非ウイルスdna挿入
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
EP3916086A1
(en)
|
2017-06-23 |
2021-12-01 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US20230193241A1
(en)
|
2017-06-25 |
2023-06-22 |
Snipr Technologies Limited |
Altering microbial populations & modifying microbiota
|
US11696572B2
(en)
|
2017-06-27 |
2023-07-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ASGR1 locus
|
US10392616B2
(en)
|
2017-06-30 |
2019-08-27 |
Arbor Biotechnologies, Inc. |
CRISPR RNA targeting enzymes and systems and uses thereof
|
HRP20220615T1
(hr)
|
2017-06-30 |
2022-06-24 |
Inscripta, Inc. |
Postupci, moduli, instrumenti i sustavi za automatiziranu obradu stanica
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
WO2019005539A1
(en)
|
2017-06-30 |
2019-01-03 |
Codexis, Inc. |
T7 POLYMERASE RNA VARIANTS
|
US20200140896A1
(en)
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
US10793841B2
(en)
|
2017-06-30 |
2020-10-06 |
Codexis, Inc. |
T7 RNA polymerase variants
|
AU2018300069A1
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
EP3427756A1
(en)
|
2017-07-14 |
2019-01-16 |
Universidad Autónoma De Barcelona (UAB) |
Therapeutic nanoconjugates and uses thereof
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
WO2019036140A1
(en)
|
2017-07-17 |
2019-02-21 |
Zymergen Inc. |
METALLO-ORGANIC STRESS MATERIALS
|
US20190316101A1
(en)
|
2017-07-18 |
2019-10-17 |
Howard Hughes Medical Institute |
Methods and compositions for genetically manipulating genes and cells
|
WO2019016310A1
(en)
|
2017-07-20 |
2019-01-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND COMPOSITIONS FOR TREATING CANCERS
|
CN109295054B
(zh)
*
|
2017-07-25 |
2024-02-06 |
广州普世利华科技有限公司 |
用于靶向病原体基因RNA的gRNA及基于C2c2的病原体基因的检测方法及试剂盒
|
US11926664B2
(en)
|
2017-07-25 |
2024-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for modulating monocytopoiesis
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
AU2018311504A1
(en)
|
2017-07-31 |
2020-03-12 |
Reflection Biotechnologies Limited |
Cellular models of and therapies for ocular diseases
|
AU2018309708A1
(en)
|
2017-07-31 |
2020-02-06 |
Regeneron Pharmaceuticals, Inc. |
CRISPR reporter non-human animals and uses thereof
|
WO2019028032A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
EMBRYONIC STEM CELLS OF TRANSGENIC MOUSE CASES AND MICE AND USES THEREOF
|
CA3065579A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Assessment of crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
EP3663310A4
(en)
|
2017-08-04 |
2021-08-11 |
Peking University |
TALE-RVD WITH SPECIFIC DETECTION OF A DNA BASE MODIFIED BY METHYLATION AND APPLICATION OF IT
|
US11624077B2
(en)
|
2017-08-08 |
2023-04-11 |
Peking University |
Gene knockout method
|
WO2019030306A1
(en)
|
2017-08-08 |
2019-02-14 |
Depixus |
ISOLATION AND IN VITRO ENRICHMENT OF NUCLEIC ACIDS USING SITE-SPECIFIC NUCLEASES
|
JP7355730B2
(ja)
|
2017-08-09 |
2023-10-03 |
ベンソン ヒル,インコーポレイティド |
ゲノムを修飾するための組成物及び方法
|
US20200260698A1
(en)
|
2017-08-18 |
2020-08-20 |
The Board Of Regents Of The University Of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
CN111263810A
(zh)
*
|
2017-08-22 |
2020-06-09 |
纳匹基因公司 |
使用多核苷酸指导的核酸内切酶的细胞器基因组修饰
|
WO2019040650A1
(en)
|
2017-08-23 |
2019-02-28 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY
|
US10738327B2
(en)
|
2017-08-28 |
2020-08-11 |
Inscripta, Inc. |
Electroporation cuvettes for automation
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
WO2019050948A1
(en)
*
|
2017-09-05 |
2019-03-14 |
Regeneron Pharmaceuticals, Inc. |
ADMINISTRATION OF A GENE EDITION SYSTEM HAVING ONLY ONE RETROVIRAL PARTICLE AND METHODS OF GENERATING AND USING
|
IL272940B1
(en)
|
2017-09-06 |
2024-02-01 |
Regeneron Pharma |
Variants linked to the interleukin-1 immunoglobulin-single receptor and their uses
|
JP2020533289A
(ja)
|
2017-09-06 |
2020-11-19 |
フレッド ハッチンソン キャンサー リサーチ センター |
養子細胞治療を改善するための方法
|
CN111051349A
(zh)
|
2017-09-06 |
2020-04-21 |
弗雷德哈钦森癌症研究中心 |
Strep-tag特异性嵌合受体及其用途
|
SG11202001792UA
(en)
|
2017-09-07 |
2020-03-30 |
Regeneron Pharma |
Solute carrier family 14 member 1 (slc14a1) variants and uses thereof
|
WO2019051097A1
(en)
|
2017-09-08 |
2019-03-14 |
The Regents Of The University Of California |
RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
|
CA3075507A1
(en)
*
|
2017-09-11 |
2019-03-14 |
The Regents Of The University Of California |
Antibody-mediated delivery of cas9 to mammalian cells
|
CN110168093B
(zh)
*
|
2017-09-12 |
2023-08-15 |
中科蓝华(广州)生物医药技术有限公司 |
一种转染细胞内寄生虫的试剂盒及其应用
|
WO2019055862A1
(en)
|
2017-09-14 |
2019-03-21 |
Fred Hutchinson Cancer Research Center |
HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
|
BR112020004268A2
(pt)
|
2017-09-18 |
2020-09-29 |
Futuragene Israel Ltd. |
construto, célula hospedeira, tecido vegetal, método para produzir uma planta, planta transgênica, método para engenheirar uma planta, planta, e, célula vegetal
|
US20200216805A1
(en)
|
2017-09-18 |
2020-07-09 |
Edigene Inc. |
Gene editing t cell and use thereof
|
US11453865B2
(en)
*
|
2017-09-19 |
2022-09-27 |
Massachusetts Institute Of Technology |
Applications of engineered Streptococcus canis Cas9 variants on single-base PAM targets
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
WO2019060469A2
(en)
*
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
CAS9 STREPTOCOCCUS CANIS AS A GENOMIC ENGINEERING PLATFORM WITH NEW PAM SPECIFICITY
|
NZ762881A
(en)
|
2017-09-19 |
2024-03-22 |
Advaxis Inc |
Compositions and methods for lyophilization of bacteria or listeria strains
|
CN111655340A
(zh)
|
2017-09-20 |
2020-09-11 |
国家医疗保健研究所 |
用于调节自噬的方法和药物组合物
|
CA3076547A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
Novel anti-hla-a2 antibodies and uses thereof
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
US11572574B2
(en)
*
|
2017-09-28 |
2023-02-07 |
Toolgen Incorporated |
Artificial genome manipulation for gene expression regulation
|
AU2018339089A1
(en)
|
2017-09-29 |
2020-04-09 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
CN111163633B
(zh)
|
2017-09-29 |
2022-09-09 |
瑞泽恩制药公司 |
包含人源化ttr基因座的非人类动物及其使用方法
|
US11845951B2
(en)
*
|
2017-09-29 |
2023-12-19 |
Toolgen Incorporated |
Gene manipulation for treatment of retinal dysfunction disorder
|
CA3074927A1
(en)
|
2017-09-30 |
2019-04-04 |
Inscripta, Inc. |
Flow through electroporation instrumentation
|
CN111447934A
(zh)
|
2017-10-06 |
2020-07-24 |
4阵营疗法公司 |
用于治疗尿素循环障碍的方法和组合物,尤其是otc缺乏症
|
MX2020003561A
(es)
|
2017-10-11 |
2020-08-03 |
Regeneron Pharma |
Inhibicion de la hsd17b13 en el tratamiento de la enfermedad hepatica en pacientes que expresan la variacion pnpla3 i148m.
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
WO2019075409A1
(en)
|
2017-10-12 |
2019-04-18 |
The Regents Of The University Of California |
ISOLATION AND IDENTIFICATION WITHOUT MICROFLUIDIC LABEL OF CELLS USING FLUORESCENCE LIFE IMAGING (FLIM)
|
RU2020115869A
(ru)
|
2017-10-16 |
2021-11-19 |
Ридженерон Фармасьютикалз, Инк. |
Варианты корнулина (crnn) и их применение
|
US11795443B2
(en)
|
2017-10-16 |
2023-10-24 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
KR20200067190A
(ko)
|
2017-10-17 |
2020-06-11 |
크리스퍼 테라퓨틱스 아게 |
A형 혈우병을 위한 유전자 편집용 조성물 및 방법
|
EP3697435A1
(en)
|
2017-10-20 |
2020-08-26 |
Fred Hutchinson Cancer Research Center |
Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
|
US11499127B2
(en)
|
2017-10-20 |
2022-11-15 |
The Regents Of The University Of California |
Multi-layered microfluidic systems for in vitro large-scale perfused capillary networks
|
US11745179B2
(en)
*
|
2017-10-20 |
2023-09-05 |
The Regents Of The University Of California |
Microfluidic systems and methods for lipoplex-mediated cell transfection
|
US20210214724A1
(en)
*
|
2017-10-23 |
2021-07-15 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
US11690856B2
(en)
|
2017-10-23 |
2023-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Compounds for treating CMV related diseases
|
KR102013798B1
(ko)
|
2017-10-25 |
2019-08-23 |
성균관대학교산학협력단 |
노화 모델 제조 방법 및 이에 의해 제조된 세포 또는 동물 노화 모델
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
CN109722414A
(zh)
|
2017-10-27 |
2019-05-07 |
博雅辑因(北京)生物科技有限公司 |
一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
MX2020004578A
(es)
|
2017-11-01 |
2020-12-03 |
Univ California |
Composiciones de casz y metodos de uso.
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
US11970719B2
(en)
|
2017-11-01 |
2024-04-30 |
The Regents Of The University Of California |
Class 2 CRISPR/Cas compositions and methods of use
|
WO2019090173A1
(en)
*
|
2017-11-02 |
2019-05-09 |
Arbor Biotechnologies, Inc. |
Novel crispr-associated transposon systems and components
|
WO2019092507A2
(en)
|
2017-11-09 |
2019-05-16 |
Crispr Therapeutics Ag |
Crispr/cas systems for treatment of dmd
|
ES2911249T3
(es)
|
2017-11-10 |
2022-05-18 |
Regeneron Pharma |
Animales no humanos que comprenden una mutación de slc30a8 y métodos de uso
|
US10940171B2
(en)
|
2017-11-10 |
2021-03-09 |
Massachusetts Institute Of Technology |
Microbial production of pure single stranded nucleic acids
|
WO2019092042A1
(en)
|
2017-11-10 |
2019-05-16 |
Novozymes A/S |
Temperature-sensitive cas9 protein
|
WO2019099943A1
(en)
|
2017-11-16 |
2019-05-23 |
Astrazeneca Ab |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
WO2019100053A1
(en)
|
2017-11-20 |
2019-05-23 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for modulating hif-2α to improve muscle generation and repair
|
WO2019101995A1
(en)
|
2017-11-27 |
2019-05-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for cardiac regeneration
|
JP7361031B2
(ja)
|
2017-11-30 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化trkb遺伝子座を含む非ヒト動物
|
WO2019109047A1
(en)
|
2017-12-01 |
2019-06-06 |
Fred Hutchinson Cancer Research Center |
Binding proteins specific for 5t4 and uses thereof
|
KR20200106159A
(ko)
|
2017-12-05 |
2020-09-11 |
버텍스 파마슈티칼스 인코포레이티드 |
크리스퍼-cas9 변형된 cd34+ 인간 조혈 줄기 및 전구 세포 및 그의 용도
|
WO2019113132A1
(en)
|
2017-12-05 |
2019-06-13 |
Caribou Biosciences, Inc. |
Modified lymphocytes
|
MX2020005875A
(es)
*
|
2017-12-05 |
2020-10-08 |
Bioplx Inc |
Métodos y composiciones para prevenir la infección microbiana.
|
WO2019113387A1
(en)
|
2017-12-07 |
2019-06-13 |
Zymergen Inc. |
Engineered biosynthetic pathways for production of (6e)-8-hydroxygeraniol by fermentation
|
AU2018378833A1
(en)
|
2017-12-08 |
2020-07-09 |
Synthetic Genomics, Inc. |
Improving algal lipid productivity via genetic modification of a TPR domain containing protein
|
CA3084825A1
(en)
|
2017-12-14 |
2019-06-20 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and their use in genome editing and other applications
|
US11661599B1
(en)
|
2017-12-14 |
2023-05-30 |
National Technology & Engineering Solutions Of Sandia, Llc |
CRISPR-Cas based system for targeting single-stranded sequences
|
KR20200098578A
(ko)
|
2017-12-15 |
2020-08-20 |
다니스코 유에스 인크. |
Cas9 변이체 및 사용 방법
|
US20200306286A1
(en)
|
2017-12-15 |
2020-10-01 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
CN111836892A
(zh)
|
2017-12-21 |
2020-10-27 |
克里斯珀医疗股份公司 |
用于治疗2a型乌谢尔综合征的材料和方法
|
EP3732189A4
(en)
|
2017-12-29 |
2022-01-19 |
Synthetic Genomics, Inc. |
GENETIC MODULATION OF PHOTOSYNTHETIC ORGANISMS FOR ENHANCED GROWTH
|
CA3087234A1
(en)
*
|
2017-12-29 |
2019-07-04 |
The Scripps Research Institute |
Unnatural base pair compositions and methods of use
|
WO2019133881A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for enginerering erythroid cells
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
WO2019136216A1
(en)
|
2018-01-05 |
2019-07-11 |
The Board Of Regents Of The University Of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
US11359208B2
(en)
|
2018-01-09 |
2022-06-14 |
Cibus Us Llc |
Shatterproof genes and mutations
|
WO2019140278A1
(en)
|
2018-01-11 |
2019-07-18 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting core binding factor antigens
|
WO2019140330A1
(en)
|
2018-01-12 |
2019-07-18 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting transferrin
|
US11268092B2
(en)
|
2018-01-12 |
2022-03-08 |
GenEdit, Inc. |
Structure-engineered guide RNA
|
CN111566121A
(zh)
|
2018-01-12 |
2020-08-21 |
巴斯夫欧洲公司 |
小麦7a染色体上决定每穗小穗数QTL的基因
|
CA3088788A1
(en)
*
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
US20210054064A1
(en)
|
2018-01-24 |
2021-02-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Antagonists of il-33 for use in methods for preventing ischemia reperfusion injusry in an organ
|
WO2019147275A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
WO2019147302A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Bauer Daniel E |
Targeting bcl11a distal regulatory elements with a cas9-cas9 fusion for fetal hemoglobin reinduction
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
CN111836893A
(zh)
|
2018-01-31 |
2020-10-27 |
德克萨斯大学系统董事会 |
用于校正人心肌细胞中肌养蛋白突变的组合物和方法
|
WO2019150309A1
(en)
|
2018-02-02 |
2019-08-08 |
Hammack Scott |
Modulators of gpr68 and uses thereof for treating and preventing diseases
|
WO2019152941A1
(en)
|
2018-02-05 |
2019-08-08 |
Caribou Biosciences, Inc. |
Engineered gut microbes for reduction of reactivation of detoxified drugs
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
US11566236B2
(en)
|
2018-02-05 |
2023-01-31 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
KR20200119239A
(ko)
|
2018-02-08 |
2020-10-19 |
지머젠 인코포레이티드 |
코리네박테리움에서 crispr을 사용하는 게놈 편집
|
KR20230022258A
(ko)
|
2018-02-15 |
2023-02-14 |
시그마-알드리치 컴퍼니., 엘엘씨 |
진핵 게놈 변형을 위한 조작된 cas9 시스템
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
JP7384811B2
(ja)
|
2018-02-16 |
2023-11-21 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白斑を処置するための方法及び組成物
|
WO2019161340A1
(en)
|
2018-02-19 |
2019-08-22 |
Yale University |
Phosphopeptide-encoding oligonucleotide libraries and methods for detecting phosphorylation-dependent molecular interactions
|
CN112020554A
(zh)
*
|
2018-02-23 |
2020-12-01 |
先锋国际良种公司 |
新颖cas9直系同源物
|
US20210079061A1
(en)
|
2018-02-26 |
2021-03-18 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
US11713472B2
(en)
|
2018-03-06 |
2023-08-01 |
The Board Of Trustees Of The University Of Illinois |
Genome editing in Archaea
|
SG11202008820WA
(en)
|
2018-03-09 |
2020-10-29 |
Advaxis Inc |
Compositions and methods for evaluating attenuation and infectivity of listeria strains
|
US20190284553A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
WO2019183150A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Casebia Therapeutics Limited Liability Partnership |
Novel rna-programmable endonuclease systems and uses thereof
|
WO2019179445A1
(en)
|
2018-03-20 |
2019-09-26 |
Tsinghua University |
Alzheimer's disease animal model and use thereof
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
BR112020019301A2
(pt)
*
|
2018-03-26 |
2021-01-05 |
National University Corporation Kobe University |
Método para modificar um sítio alvo de um dna de fita dupla de uma célula.
|
EP3781196B1
(en)
*
|
2018-03-27 |
2024-03-06 |
G+Flas Life Sciences |
Sequence-specific in vivo cell targeting
|
AU2019241967A1
(en)
|
2018-03-29 |
2020-11-19 |
Inscripta, Inc. |
Automated control of cell growth rates for induction and transformation
|
WO2019193375A1
(en)
|
2018-04-04 |
2019-10-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fzd7 inhibitors for the treatment of retinal neovascularization
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
AU2019250692A1
(en)
|
2018-04-13 |
2020-11-05 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for Interleukin-23 receptor
|
US10376889B1
(en)
|
2018-04-13 |
2019-08-13 |
Inscripta, Inc. |
Automated cell processing instruments comprising reagent cartridges
|
AU2019256287A1
(en)
|
2018-04-17 |
2020-11-12 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
JP2021521788A
(ja)
|
2018-04-19 |
2021-08-30 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
ゲノム編集のための組成物および方法
|
US10858761B2
(en)
|
2018-04-24 |
2020-12-08 |
Inscripta, Inc. |
Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
|
WO2019209926A1
(en)
|
2018-04-24 |
2019-10-31 |
Inscripta, Inc. |
Automated instrumentation for production of peptide libraries
|
US10557216B2
(en)
|
2018-04-24 |
2020-02-11 |
Inscripta, Inc. |
Automated instrumentation for production of T-cell receptor peptide libraries
|
AU2019260687B2
(en)
|
2018-04-27 |
2022-09-22 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
US20210239681A1
(en)
|
2018-04-27 |
2021-08-05 |
Advaxis, Inc. |
Compositions and methods for evaluating potency of listeria-based immunotherapeutics
|
CN112105732A
(zh)
*
|
2018-05-10 |
2020-12-18 |
先正达参股股份有限公司 |
用于多核苷酸的靶向编辑的方法和组合物
|
CA3098874A1
(en)
|
2018-05-10 |
2019-11-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Gene therapy methods and compositions using auxotrophic regulatable cells
|
WO2019217964A1
(en)
|
2018-05-11 |
2019-11-14 |
Lupagen, Inc. |
Systems and methods for closed loop, real-time modifications of patient cells
|
JP2021523745A
(ja)
|
2018-05-16 |
2021-09-09 |
シンテゴ コーポレイション |
ガイドrna設計および使用のための方法およびシステム
|
WO2019226603A1
(en)
*
|
2018-05-22 |
2019-11-28 |
The Regents Of The University Of California |
Trna/pre-mirna compositions and use in treating cancer
|
EP3572512A1
(en)
|
2018-05-24 |
2019-11-27 |
B.R.A.I.N. Ag |
A method for engineering a protein
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
KR20210089629A
(ko)
|
2018-06-05 |
2021-07-16 |
라이프에디트 테라퓨틱스, 인크. |
Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
|
WO2019236893A2
(en)
*
|
2018-06-07 |
2019-12-12 |
Allen Institute |
Stem cell lines containing endogenous, differentially-expressed tagged proteins, methods of production, and use thereof
|
FR3082208A1
(fr)
|
2018-06-11 |
2019-12-13 |
Fondation Mediterranee Infection |
Methode de modification d'une sequence cible d'acide nucleique d'une cellule hote
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
WO2019246488A1
(en)
|
2018-06-21 |
2019-12-26 |
Duke University |
Compositions and methods for the production of pyruvic acid and related products using dynamic metabolic control
|
EP3814369A1
(en)
|
2018-06-29 |
2021-05-05 |
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis |
Tweak-receptor agonists for use in combination with immunotherapy of a cancer
|
WO2020005383A1
(en)
|
2018-06-30 |
2020-01-02 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
EP3821012A4
(en)
|
2018-07-13 |
2022-04-20 |
The Regents of The University of California |
RETROTRANSPOSON-BASED DELIVERY VEHICLE AND METHOD OF USE THEREOF
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
WO2020023655A1
(en)
*
|
2018-07-24 |
2020-01-30 |
Flagship Pioneering, Inc. |
Compositions comprising circular polyribonucleotides and uses thereof
|
EP3830301B1
(en)
|
2018-08-01 |
2024-05-22 |
Mammoth Biosciences, Inc. |
Programmable nuclease compositions and methods of use thereof
|
WO2020028617A1
(en)
|
2018-08-01 |
2020-02-06 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for improving embryo development
|
CA3107268A1
(en)
|
2018-08-07 |
2020-02-13 |
Modalis Therapeutics Corporation |
Novel transcription activator
|
US20210292389A1
(en)
|
2018-08-10 |
2021-09-23 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
US11142740B2
(en)
|
2018-08-14 |
2021-10-12 |
Inscripta, Inc. |
Detection of nuclease edited sequences in automated modules and instruments
|
US10752874B2
(en)
|
2018-08-14 |
2020-08-25 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
US10532324B1
(en)
|
2018-08-14 |
2020-01-14 |
Inscripta, Inc. |
Instruments, modules, and methods for improved detection of edited sequences in live cells
|
WO2020086144A2
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
|
JP2021534752A
(ja)
|
2018-08-22 |
2021-12-16 |
フレッド ハッチンソン キャンサー リサーチ センター |
Kras抗原またはher2抗原を標的とする免疫療法
|
IL280951B1
(en)
|
2018-08-23 |
2024-04-01 |
Sangamo Therapeutics Inc |
Engineered target-specific base editors
|
KR20220036908A
(ko)
|
2018-08-28 |
2022-03-23 |
보르 바이오파마 인크. |
유전자 조작된 조혈 줄기 세포 및 그의 용도
|
CN112930393A
(zh)
|
2018-08-28 |
2021-06-08 |
福瑞德哈金森癌症研究中心 |
结合诱导的Notch信号传导的过继T细胞疗法的方法和组合物
|
AU2019363487A1
(en)
|
2018-08-30 |
2021-04-15 |
Inscripta, Inc. |
Improved detection of nuclease edited sequences in automated modules and instruments
|
MX2021002266A
(es)
|
2018-08-31 |
2021-05-27 |
Univ Yale |
Composiciones y metodos para aumentar la edicion de genes basados en nucleasa y triplex.
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
EP3846909A1
(en)
|
2018-09-05 |
2021-07-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating asthma and allergic diseases
|
US20210198642A1
(en)
|
2018-09-07 |
2021-07-01 |
Astrazeneca Ab |
Compositions and methods for improved nucleases
|
US20200080107A1
(en)
|
2018-09-07 |
2020-03-12 |
Crispr Therapeutics Ag |
Universal donor cells
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
JP7222075B2
(ja)
|
2018-09-13 |
2023-02-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
C3糸球体症のモデルとしての補体因子h遺伝子ノックアウトラット
|
JP2022501374A
(ja)
|
2018-09-21 |
2022-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
糖尿病を治療するための方法及び組成物、ならびに分泌タンパク質をコードするmRNAを濃縮する方法
|
WO2020068702A1
(en)
|
2018-09-24 |
2020-04-02 |
Fred Hutchinson Cancer Research Center |
Chimeric receptor proteins and uses thereof
|
EP3856772A1
(en)
|
2018-09-25 |
2021-08-04 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
|
GB201815820D0
(en)
|
2018-09-28 |
2018-11-14 |
Univ Wageningen |
Off-target activity inhibitors for guided endonucleases
|
WO2020070062A1
(en)
|
2018-10-01 |
2020-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
JP7288915B2
(ja)
|
2018-10-04 |
2023-06-08 |
株式会社カネカ |
植物のゲノム編集に用いられるdna構築物
|
US20210347898A1
(en)
|
2018-10-09 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of alpha-v-integrin (cd51) inhibitors for the treatment of cardiac fibrosis
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
CN113348247A
(zh)
|
2018-10-15 |
2021-09-03 |
泰莱托恩基金会 |
基因组编辑方法与构建体
|
EP3866583A1
(en)
|
2018-10-16 |
2021-08-25 |
Pioneer Hi-Bred International, Inc. |
Genome edited fine mapping and causal gene identification
|
EP3867377A1
(en)
|
2018-10-17 |
2021-08-25 |
CRISPR Therapeutics AG |
Compositions and methods for delivering transgenes
|
CN113260701A
(zh)
|
2018-10-18 |
2021-08-13 |
英特利亚治疗股份有限公司 |
用于表达因子ix的组合物和方法
|
KR20210102882A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
핵산 구조체 및 사용 방법
|
JP2022505381A
(ja)
|
2018-10-18 |
2022-01-14 |
インテリア セラピューティクス,インコーポレーテッド |
アルファ1アンチトリプシン欠乏症を治療するための組成物及び方法
|
WO2020079162A1
(en)
|
2018-10-18 |
2020-04-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for inducing full ablation of hematopoiesis
|
KR20210102883A
(ko)
|
2018-10-18 |
2021-08-20 |
인텔리아 테라퓨틱스, 인크. |
알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
|
US11214781B2
(en)
|
2018-10-22 |
2022-01-04 |
Inscripta, Inc. |
Engineered enzyme
|
CN113227368B
(zh)
|
2018-10-22 |
2023-07-07 |
因思科瑞普特公司 |
工程化酶
|
US11946047B2
(en)
*
|
2018-10-23 |
2024-04-02 |
Texas Tech University System |
Treatment strategies against anthrax by interfering with critical host factors
|
UY38427A
(es)
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
CA3117805A1
(en)
|
2018-10-31 |
2020-05-07 |
Zymergen Inc. |
Multiplexed deterministic assembly of dna libraries
|
EP3874048A1
(en)
*
|
2018-11-01 |
2021-09-08 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
CA3119188A1
(en)
|
2018-11-09 |
2020-05-14 |
Fred Hutchinson Cancer Research Center |
T cell receptors specific for mesothelin and their use in immunotherapy
|
JP7069426B2
(ja)
|
2018-11-16 |
2022-05-17 |
アステラス製薬株式会社 |
ユートロフィン遺伝子を標的とした筋ジストロフィーの治療方法
|
AU2019390691A1
(en)
|
2018-11-28 |
2021-05-13 |
Keygene N.V. |
Targeted enrichment by endonuclease protection
|
WO2020113135A1
(en)
*
|
2018-11-29 |
2020-06-04 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating rna
|
WO2020112195A1
(en)
|
2018-11-30 |
2020-06-04 |
Yale University |
Compositions, technologies and methods of using plerixafor to enhance gene editing
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
CN113423823A
(zh)
*
|
2018-12-12 |
2021-09-21 |
国立大学法人九州大学 |
经基因组编辑的细胞的制造方法
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
US20220073890A1
(en)
|
2018-12-14 |
2022-03-10 |
Pioneer Hi-Bred International, Inc. |
Novel crispr-cas systems for genome editing
|
EP3898958A1
(en)
*
|
2018-12-17 |
2021-10-27 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
WO2020128478A1
(en)
|
2018-12-19 |
2020-06-25 |
King's College London |
Immunotherapeutic methods and compositions
|
JP7449291B2
(ja)
|
2018-12-20 |
2024-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヌクレアーゼ媒介リピート伸長
|
US20220143136A1
(en)
|
2018-12-21 |
2022-05-12 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
CN113874395A
(zh)
*
|
2018-12-24 |
2021-12-31 |
威特拉公司 |
鉴定表位和互补位的方法
|
WO2020136216A1
(en)
|
2018-12-27 |
2020-07-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of identifying subjects having or at risk of having a coagulation related disorder
|
BR112021012665A2
(pt)
|
2018-12-27 |
2021-11-03 |
Lifeedit Therapeutics Inc |
Polipeptídeos úteis para edição de genes e métodos de uso
|
JP2022515639A
(ja)
*
|
2018-12-31 |
2022-02-21 |
エイチティージー モレキュラー ダイアグノスティクス, インコーポレイテッド |
同じ試料中のdnaおよびrnaを検出する方法
|
AU2020205150A1
(en)
|
2019-01-03 |
2021-07-22 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
WO2020142754A2
(en)
|
2019-01-04 |
2020-07-09 |
Mammoth Biosciences, Inc. |
Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
|
TW202043256A
(zh)
*
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
CA3145881A1
(en)
|
2019-01-15 |
2020-07-23 |
Seminis Vegetable Seeds, Inc. |
Green bean plants with improved resistance to sclerotinia sclerotiorum and genetic markers therefor
|
US20220119516A1
(en)
|
2019-01-16 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Variants of erythroferrone and their use
|
EP3911367A1
(en)
|
2019-01-17 |
2021-11-24 |
Universitat Autónoma De Barcelona (UAB) |
Therapeutic nanoconjugates and uses thereof
|
US11419932B2
(en)
|
2019-01-24 |
2022-08-23 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
WO2020160125A1
(en)
*
|
2019-01-29 |
2020-08-06 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising an endonuclease and methods for purifying an endonuclease
|
EP3921031A1
(en)
|
2019-02-04 |
2021-12-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for modulating blood-brain barrier
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
US20220145330A1
(en)
|
2019-02-10 |
2022-05-12 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Modified mitochondrion and methods of use thereof
|
WO2020168362A1
(en)
|
2019-02-15 |
2020-08-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
US10947517B2
(en)
|
2019-02-15 |
2021-03-16 |
Sigma-Aldrich Co. Llc |
CRISPR/Cas fusion proteins and systems
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
JP2022521513A
(ja)
|
2019-02-20 |
2022-04-08 |
フレッド ハッチンソン キャンサー リサーチ センター |
Rasネオ抗原に特異的な結合タンパク質およびその使用
|
US20220290120A1
(en)
|
2019-02-25 |
2022-09-15 |
Novome Biotechnologies, Inc. |
Plasmids for gene editing
|
WO2020180699A1
(en)
*
|
2019-03-01 |
2020-09-10 |
Arbor Biotechnologies, Inc. |
Novel crispr dna targeting enzymes and systems
|
EP3935184A1
(en)
|
2019-03-04 |
2022-01-12 |
King Abdullah University Of Science And Technology |
Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
|
AU2020231380A1
(en)
|
2019-03-07 |
2021-09-23 |
The Regents Of The University Of California |
CRISPR-Cas effector polypeptides and methods of use thereof
|
CA3129871A1
(en)
|
2019-03-08 |
2020-09-17 |
Zymergen Inc. |
Iterative genome editing in microbes
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
AU2020237043A1
(en)
|
2019-03-11 |
2021-09-30 |
Fred Hutchinson Cancer Center |
High avidity WT1 T cell receptors and uses thereof
|
CN113825834A
(zh)
|
2019-03-11 |
2021-12-21 |
索伦托药业有限公司 |
使用rna引导的核酸内切酶进行dna构建体整合的改进工艺
|
US11781131B2
(en)
|
2019-03-18 |
2023-10-10 |
Regeneron Pharmaceuticals, Inc. |
CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
CN113631700A
(zh)
|
2019-03-18 |
2021-11-09 |
瑞泽恩制药公司 |
用于鉴定tau接种或聚集的基因修饰因子的CRISPR/Cas筛选平台
|
WO2020191153A2
(en)
*
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
CN113631713A
(zh)
|
2019-03-25 |
2021-11-09 |
因思科瑞普特公司 |
酵母中的同时多重基因组编辑
|
US11001831B2
(en)
|
2019-03-25 |
2021-05-11 |
Inscripta, Inc. |
Simultaneous multiplex genome editing in yeast
|
EP3947425A1
(en)
|
2019-03-27 |
2022-02-09 |
Pioneer Hi-Bred International, Inc. |
Plant explant transformation
|
WO2020193740A1
(en)
|
2019-03-28 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
US20220249511A1
(en)
|
2019-03-29 |
2022-08-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
MX2021011956A
(es)
|
2019-04-03 |
2021-12-15 |
Regeneron Pharma |
Metodos y composiciones para la insercion de secuencias codificantes de anticuerpos en un locus de puerto seguro.
|
KR102487901B1
(ko)
|
2019-04-04 |
2023-01-12 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 변형의 표적화 벡터로의 무흔적 도입을 위한 방법
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
CN113646429A
(zh)
|
2019-04-05 |
2021-11-12 |
国立大学法人大阪大学 |
敲入细胞的制作方法
|
US20220162621A1
(en)
|
2019-04-05 |
2022-05-26 |
Danisco Us Inc |
Methods For Polynucleotide Integration Into The Genome Of Bacillus Using Dual Circular Recombinant DNA Constructs And Compositions Thereof
|
EP3947662A1
(en)
|
2019-04-05 |
2022-02-09 |
Danisco US Inc. |
Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof
|
WO2020208082A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating cmv related diseases
|
JP2022528722A
(ja)
|
2019-04-12 |
2022-06-15 |
アストラゼネカ・アクチエボラーグ |
改善された遺伝子編集のための組成物及び方法
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
JP2022531347A
(ja)
*
|
2019-04-30 |
2022-07-06 |
エメンドバイオ・インコーポレイテッド |
新規のomni-50crisprヌクレアーゼ
|
US20220193142A1
(en)
|
2019-04-30 |
2022-06-23 |
Edigene Inc. |
Method for predicting effectiveness of treatment of hemoglobinopathy
|
US11692197B2
(en)
|
2019-05-06 |
2023-07-04 |
Inari Agriculture Technology, Inc. |
Delivery of biological molecules to plant cells
|
US20210047649A1
(en)
|
2019-05-08 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
US20220220495A1
(en)
|
2019-05-10 |
2022-07-14 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
JP2022534813A
(ja)
|
2019-05-23 |
2022-08-03 |
ブイオーアール バイオファーマ インコーポレーテッド |
Cd33改変のための組成物および方法
|
WO2020239623A1
(en)
|
2019-05-24 |
2020-12-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of ngal inhibitors for the treating chronic wound
|
WO2020245208A1
(en)
|
2019-06-04 |
2020-12-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
|
EP3980012A1
(en)
|
2019-06-04 |
2022-04-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
A neuropilin antagonist in combination with a p38alpha-kinase inhibitor for the treatment of cancer
|
JP2022534867A
(ja)
|
2019-06-04 |
2022-08-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
|
CA3139122C
(en)
|
2019-06-06 |
2023-04-25 |
Inscripta, Inc. |
Curing for recursive nucleic acid-guided cell editing
|
BR112021022722A2
(pt)
|
2019-06-07 |
2022-01-04 |
Regeneron Pharma |
Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
|
AU2020289591A1
(en)
|
2019-06-07 |
2021-12-23 |
Scribe Therapeutics Inc. |
Engineered CasX systems
|
WO2020249769A1
(en)
|
2019-06-14 |
2020-12-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
|
EP3813522A1
(en)
|
2019-06-14 |
2021-05-05 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
US10907125B2
(en)
|
2019-06-20 |
2021-02-02 |
Inscripta, Inc. |
Flow through electroporation modules and instrumentation
|
US10920189B2
(en)
|
2019-06-21 |
2021-02-16 |
Inscripta, Inc. |
Genome-wide rationally-designed mutations leading to enhanced lysine production in E. coli
|
SG11202112092TA
(en)
|
2019-06-25 |
2021-11-29 |
Inari Agriculture Technology Inc |
Improved homology dependent repair genome editing
|
US10927385B2
(en)
|
2019-06-25 |
2021-02-23 |
Inscripta, Inc. |
Increased nucleic-acid guided cell editing in yeast
|
US11905532B2
(en)
|
2019-06-25 |
2024-02-20 |
Massachusetts Institute Of Technology |
Compositions and methods for molecular memory storage and retrieval
|
KR20220024134A
(ko)
|
2019-06-27 |
2022-03-03 |
리제너론 파마슈티칼스 인코포레이티드 |
Tdp-43 단백질이상질환 모델링
|
WO2021001431A1
(en)
|
2019-07-02 |
2021-01-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer
|
US20220354863A1
(en)
|
2019-07-02 |
2022-11-10 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods for the prophylactic treatment of cancer in patients suffering from pancreatitis
|
GB201909597D0
(en)
|
2019-07-03 |
2019-08-14 |
Univ Wageningen |
Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
|
AU2020313004A1
(en)
|
2019-07-12 |
2022-03-10 |
Riken |
Therapeutic agent for disease caused by dominant mutant gene
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
EP3999091A1
(en)
|
2019-07-15 |
2022-05-25 |
MedImmune Limited |
Tripartite systems for protein dimerization and methods of use
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
EP4003325A1
(en)
|
2019-07-24 |
2022-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
|
WO2021023644A1
(en)
|
2019-08-02 |
2021-02-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing granzyme b for providing cardioprotection in a subject who experienced a myocardial infarction
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
JP2022545385A
(ja)
*
|
2019-08-12 |
2022-10-27 |
ライフエディット セラピューティクス,インコーポレイティド |
Rna誘導ヌクレアーゼ及びその活性断片及び変異体ならびに使用方法
|
EP4017872A1
(en)
|
2019-08-20 |
2022-06-29 |
Fred Hutchinson Cancer Center |
T-cell immunotherapy specific for wt-1
|
KR20220047380A
(ko)
|
2019-08-28 |
2022-04-15 |
보르 바이오파마 인크. |
Cll1 변형을 위한 조성물 및 방법
|
WO2021041541A1
(en)
*
|
2019-08-28 |
2021-03-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modified circular rnas and methods of use thereof
|
US20220333116A1
(en)
|
2019-08-28 |
2022-10-20 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
CN115151275A
(zh)
|
2019-08-30 |
2022-10-04 |
耶鲁大学 |
用于向细胞递送核酸的组合物和方法
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
JP2022547105A
(ja)
|
2019-09-04 |
2022-11-10 |
博雅▲輯▼因(北京)生物科技有限公司 |
オフターゲット評価に基づく遺伝子編集治療の評価方法
|
MX2022002642A
(es)
|
2019-09-05 |
2022-06-14 |
Benson Hill Inc |
Composiciones y metodos para modificar genomas.
|
JP2022547053A
(ja)
|
2019-09-05 |
2022-11-10 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
ユニバーサルドナー細胞
|
EP4025690A1
(en)
|
2019-09-05 |
2022-07-13 |
CRISPR Therapeutics AG |
Universal donor cells
|
WO2021044012A1
(en)
|
2019-09-05 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment and pronostic of acute myeloid leukemia
|
CN114729343A
(zh)
*
|
2019-09-10 |
2022-07-08 |
科学方案有限责任公司 |
新的2类ii型和v型crispr-cas rna指导的内切核酸酶
|
WO2021047775A1
(en)
|
2019-09-12 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of tgfb/activinb signaling pathway for the treatment of patients suffering from medulloblastoma group 3
|
AU2020344905A1
(en)
|
2019-09-12 |
2022-04-28 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
CN114616002A
(zh)
|
2019-09-13 |
2022-06-10 |
瑞泽恩制药公司 |
使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス, インコーポレイテッド |
肝細胞核因子4-アルファ(HNF4α)遺伝子発現をモジュレートするための組成物および方法
|
US11542513B2
(en)
|
2019-09-26 |
2023-01-03 |
Seminis Vegetable Seeds, Inc. |
Lettuce plants having resistance to Nasonovia ribisnigri biotype Nr:1
|
WO2021063968A1
(en)
|
2019-09-30 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and composition for diagnosing chronic obstructive pulmonary disease
|
US20220354811A1
(en)
|
2019-10-03 |
2022-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
WO2021067788A1
(en)
*
|
2019-10-03 |
2021-04-08 |
Artisan Development Labs, Inc. |
Crispr systems with engineered dual guide nucleic acids
|
WO2021069387A1
(en)
|
2019-10-07 |
2021-04-15 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
KR20220079832A
(ko)
|
2019-10-11 |
2022-06-14 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
WO2021076053A1
(en)
*
|
2019-10-15 |
2021-04-22 |
Agency For Science, Technology And Research |
Assays for measuring nucleic acid modifying enzyme activity
|
WO2021078359A1
(en)
|
2019-10-21 |
2021-04-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of cubilin for the treatment of chronic kidney diseases
|
US11591607B2
(en)
*
|
2019-10-24 |
2023-02-28 |
Pairwise Plants Services, Inc. |
Optimized CRISPR-Cas nucleases and base editors and methods of use thereof
|
US20240122938A1
(en)
|
2019-10-29 |
2024-04-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating uveal melanoma
|
EP4054651A1
(en)
|
2019-11-08 |
2022-09-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr and aav strategies for x-linked juvenile retinoschisis therapy
|
CN114929862A
(zh)
*
|
2019-11-13 |
2022-08-19 |
克里斯珀医疗股份公司 |
用于制备表达嵌合抗原受体的t细胞的生产方法
|
KR20220097985A
(ko)
*
|
2019-11-13 |
2022-07-08 |
크리스퍼 테라퓨틱스 아게 |
Car-t 세포의 제조 방법
|
WO2021101950A1
(en)
|
2019-11-19 |
2021-05-27 |
Danisco Us Inc |
Selection marker free methods for modifying the genome of bacillus and compositions thereof
|
US11203762B2
(en)
|
2019-11-19 |
2021-12-21 |
Inscripta, Inc. |
Methods for increasing observed editing in bacteria
|
US20230037413A1
(en)
|
2019-11-20 |
2023-02-09 |
Corbion Biotech, Inc. |
Sucrose invertase variants
|
CN110938659B
(zh)
*
|
2019-11-22 |
2022-05-10 |
广东省微生物研究所(广东省微生物分析检测中心) |
一种提高纤维堆囊菌埃博霉素产量的dCas9载体及其构建方法
|
EP4061944A1
(en)
|
2019-11-22 |
2022-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
AR120563A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quimérico cd19 y cd22 y sus usos
|
CA3158729A1
(en)
|
2019-11-27 |
2021-06-03 |
Virginia Kincaid |
Multipartite luciferase peptides and polypeptides
|
EP4065224A1
(en)
|
2019-11-27 |
2022-10-05 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of neuropilin antagonists for the treatment of endometriosis
|
US20230002455A1
(en)
|
2019-11-29 |
2023-01-05 |
Basf Se |
Increasing resistance against fungal infections in plants
|
JP2023504264A
(ja)
|
2019-12-03 |
2023-02-02 |
ビーム セラピューティクス インク. |
合成ガイドrna、組成物、方法、およびそれらの使用
|
EP4069852A1
(en)
|
2019-12-03 |
2022-10-12 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
US10883095B1
(en)
|
2019-12-10 |
2021-01-05 |
Inscripta, Inc. |
Mad nucleases
|
US10704033B1
(en)
|
2019-12-13 |
2020-07-07 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
GB201918586D0
(en)
|
2019-12-17 |
2020-01-29 |
Patterson James |
Engineered platelets for targeted delivery of a therapeutic agent
|
JP2023507566A
(ja)
|
2019-12-18 |
2023-02-24 |
インスクリプタ, インコーポレイテッド |
核酸誘導ヌクレアーゼ編集済み細胞のin vivo検出のためのカスケード/dCas3相補性アッセイ
|
KR20220116504A
(ko)
|
2019-12-19 |
2022-08-23 |
바스프 에스이 |
정밀 화학물의 제조에서 공시 수율, 탄소-전환-효율 및 탄소 기질 적응성의 증가
|
BR112022011895A2
(pt)
|
2019-12-20 |
2022-09-06 |
Basf Se |
Diminuição da toxidez de terpenos e aumento da produção potencial em microrganismos
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
EP3842452A1
(en)
|
2019-12-26 |
2021-06-30 |
Universitat Autònoma de Barcelona |
Scaffold proteins and therapeutic nanoconjugates based on nidogen
|
US20230059884A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Universal car-t targeting t-cell lymphoma cell and preparation method therefor and use thereof
|
US20230054266A1
(en)
|
2019-12-30 |
2023-02-23 |
Edigene Biotechnology Inc. |
Method for purifying ucart cell and use thereof
|
US11859172B2
(en)
|
2020-01-02 |
2024-01-02 |
The Trustees Of Columbia University In The City Of New York |
Programmable and portable CRISPR-Cas transcriptional activation in bacteria
|
CN110982820A
(zh)
*
|
2020-01-03 |
2020-04-10 |
云南中烟工业有限责任公司 |
一种烟草单倍体的基因编辑方法
|
US10689669B1
(en)
|
2020-01-11 |
2020-06-23 |
Inscripta, Inc. |
Automated multi-module cell processing methods, instruments, and systems
|
US20230076415A1
(en)
|
2020-01-17 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2021148447A1
(en)
|
2020-01-21 |
2021-07-29 |
Limagrain Europe |
Wheat haploid inducer plant and uses
|
US20210284978A1
(en)
*
|
2020-01-24 |
2021-09-16 |
The General Hospital Corporation |
Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
|
US20210261932A1
(en)
*
|
2020-01-24 |
2021-08-26 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
WO2021154706A1
(en)
|
2020-01-27 |
2021-08-05 |
Inscripta, Inc. |
Electroporation modules and instrumentation
|
AU2021212668A1
(en)
|
2020-01-28 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized PNPLA3 locus and methods of use
|
US20230312635A1
(en)
|
2020-01-29 |
2023-10-05 |
Sumitomo Chemical Company, Limited |
Method for producing nucleic acid oligomer
|
CN115003680A
(zh)
|
2020-01-29 |
2022-09-02 |
住友化学株式会社 |
制备核酸寡聚物的方法
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
US20230357784A1
(en)
|
2020-02-21 |
2023-11-09 |
Limagrain Europe |
Prime editing technology for plant genome engineering
|
CN115485300A
(zh)
|
2020-02-26 |
2022-12-16 |
索伦托药业有限公司 |
具有通用掩蔽部分的可活化的抗原结合蛋白
|
WO2021178556A1
(en)
|
2020-03-04 |
2021-09-10 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
WO2021183720A1
(en)
|
2020-03-11 |
2021-09-16 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
JP2023517992A
(ja)
|
2020-03-12 |
2023-04-27 |
インスティチュート フォー ベーシック サイエンス |
ゲノム配列変異を有する細胞死滅誘導用組成物及び該組成物を用いた細胞死滅誘導方法
|
CN115667505A
(zh)
|
2020-03-19 |
2023-01-31 |
因特利亚治疗公司 |
用于定向基因组编辑的方法和组合物
|
AU2021237790A1
(en)
|
2020-03-20 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Chimeric antigen receptor specific for human CD45RC and uses thereof
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US20240099210A1
(en)
|
2020-03-26 |
2024-03-28 |
National Agriculture And Food Research Organization |
Method for producing temperature-sensitive male sterile plant
|
KR20220160010A
(ko)
|
2020-03-27 |
2022-12-05 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
EP4132954A1
(en)
|
2020-04-08 |
2023-02-15 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cdon inhibitors for the treatment of endothelial dysfunction
|
US20230340538A1
(en)
|
2020-04-08 |
2023-10-26 |
Astrazeneca Ab |
Compositions and methods for improved site-specific modification
|
WO2021217083A1
(en)
|
2020-04-24 |
2021-10-28 |
Sorrento Therapeutics, Inc. |
Memory dimeric antigen receptors
|
TW202208626A
(zh)
|
2020-04-24 |
2022-03-01 |
美商生命編輯公司 |
Rna引導核酸酶及其活性片段與變體,以及使用方法
|
US20210332388A1
(en)
|
2020-04-24 |
2021-10-28 |
Inscripta, Inc. |
Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
|
CN115667504A
(zh)
|
2020-04-27 |
2023-01-31 |
诺华股份有限公司 |
用于眼细胞疗法的方法和组合物
|
WO2021226141A1
(en)
|
2020-05-04 |
2021-11-11 |
Saliogen Therapeutics, Inc. |
Transposition-based therapies
|
CA3179710A1
(en)
|
2020-05-05 |
2021-11-11 |
Andrew Mark CIGAN |
Methods for improving the health of porcine species by targeted inactivation of cd163
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
WO2021224401A1
(en)
|
2020-05-07 |
2021-11-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for determining a reference range of β-galactose exposure platelet
|
KR20230019843A
(ko)
|
2020-05-08 |
2023-02-09 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적 이중 가닥 뉴클레오티드 서열의 두 가닥의 동시 편집을 위한 방법 및 조성물
|
US20230279438A1
(en)
|
2020-05-13 |
2023-09-07 |
Inserm (Institut National De La Santé Et La Recherche Médicale) |
Base editing approaches for the treatment of betahemoglobinopathies
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
US11787841B2
(en)
|
2020-05-19 |
2023-10-17 |
Inscripta, Inc. |
Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
|
US11263022B2
(en)
*
|
2020-05-21 |
2022-03-01 |
Microsoft Technology Licensing, Llc |
Mechanism to turn on/off post-processing features in the device media foundation transform
|
WO2021248052A1
(en)
|
2020-06-05 |
2021-12-09 |
The Broad Institute, Inc. |
Compositions and methods for treating neoplasia
|
US20230235326A1
(en)
|
2020-06-05 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating ocular diseases
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
CN111748539B
(zh)
*
|
2020-06-11 |
2021-10-22 |
中国农业科学院农产品加工研究所 |
CRISPR/LpCas9基因编辑系统及其应用
|
WO2021255204A1
(en)
|
2020-06-18 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New strategy for treating pancreatic cancer
|
WO2021263146A2
(en)
|
2020-06-26 |
2021-12-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ace2 locus
|
CN115997017A
(zh)
*
|
2020-07-08 |
2023-04-21 |
杰克逊实验室 |
支持人类先天免疫功能的转基因小鼠模型
|
WO2022008597A1
(en)
|
2020-07-08 |
2022-01-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of infectious diseases
|
BR112022026885A2
(pt)
|
2020-07-09 |
2023-01-24 |
Modalis Therapeutics Corp |
Método para tratar doença de alzheimer por direcionamento de gene mapt
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
AU2021204717A1
(en)
|
2020-07-15 |
2022-02-03 |
Seminis Vegetable Seeds, Inc. |
Green Bean Plants with Improved Disease Resistance
|
AU2021310363A1
(en)
|
2020-07-15 |
2023-03-16 |
LifeEDIT Therapeutics, Inc. |
Uracil stabilizing proteins and active fragments and variants thereof and methods of use
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022032085A1
(en)
|
2020-08-07 |
2022-02-10 |
The Jackson Laboratory |
Targeted sequence insertion compositions and methods
|
CA3188988A1
(en)
|
2020-08-13 |
2022-02-17 |
Sidi CHEN |
Compositions and methods for engineering and selection of car t cells with desired phenotypes
|
US20230295650A1
(en)
|
2020-08-18 |
2023-09-21 |
Pioneer Hi-Bred International, Inc. |
Multiple disease resistance genes and genomic stacks thereof
|
AU2021329375A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
CA3189510A1
(en)
|
2020-08-20 |
2022-02-24 |
Julyun OH |
Compositions and methods for treating egfr positive cancers
|
AU2021329371A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
EP4204565A1
(en)
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
EP4204564A1
(en)
|
2020-08-28 |
2023-07-05 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
US20230265214A1
(en)
|
2020-08-31 |
2023-08-24 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
CA3194019A1
(en)
|
2020-09-04 |
2022-03-10 |
National University Corporation Kobe University |
Miniaturized cytidine deaminase-containing complex for modifying double-stranded dna
|
AU2021339805A1
(en)
|
2020-09-11 |
2023-05-25 |
LifeEDIT Therapeutics, Inc. |
Dna modifying enzymes and active fragments and variants thereof and methods of use
|
JP2023541458A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Cd5修飾のための化合物および方法
|
WO2022056489A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd38 modification
|
US11299731B1
(en)
|
2020-09-15 |
2022-04-12 |
Inscripta, Inc. |
CRISPR editing to embed nucleic acid landing pads into genomes of live cells
|
EP4214311A2
(en)
|
2020-09-18 |
2023-07-26 |
Artisan Development Labs, Inc. |
Constructs and uses thereof for efficient and specific genome editing
|
WO2022061115A1
(en)
|
2020-09-18 |
2022-03-24 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
EP4217387A2
(en)
|
2020-09-24 |
2023-08-02 |
Fred Hutchinson Cancer Center |
Immunotherapy targeting sox2 antigens
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
KR20230074205A
(ko)
|
2020-09-24 |
2023-05-26 |
스미또모 가가꾸 가부시끼가이샤 |
핵산 올리고머의 제조 방법
|
AU2021350024A1
(en)
*
|
2020-09-24 |
2023-05-04 |
Flagship Pioneering Innovations V, Inc. |
Compositions and methods for inhibiting gene expression
|
WO2022067240A1
(en)
|
2020-09-28 |
2022-03-31 |
Vor Biopharma, Inc. |
Compositions and methods for cd6 modification
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
CA3191387A1
(en)
|
2020-09-30 |
2022-04-07 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
WO2022072643A1
(en)
|
2020-09-30 |
2022-04-07 |
Vor Biopharma Inc. |
Compositions and methods for cd30 gene modification
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
JP2023545403A
(ja)
|
2020-10-02 |
2023-10-30 |
リマグレン、ヨーロッパ |
Crisprを介した指令コドン書換え
|
US20230375571A1
(en)
|
2020-10-05 |
2023-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling
|
WO2022076353A1
(en)
|
2020-10-06 |
2022-04-14 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for treating mage-a1-expressing disease
|
JP2023543602A
(ja)
|
2020-10-06 |
2023-10-17 |
キージーン ナムローゼ フェンノートシャップ |
標的化された配列付加
|
WO2022079020A1
(en)
|
2020-10-13 |
2022-04-21 |
Centre National De La Recherche Scientifique (Cnrs) |
Targeted-antibacterial-plasmids combining conjugation and crispr /cas systems and uses thereof
|
WO2022087235A1
(en)
|
2020-10-21 |
2022-04-28 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
US20240000846A1
(en)
|
2020-10-27 |
2024-01-04 |
Vor Biopharma Inc. |
Compositions and methods for treating hematopoietic malignancy
|
WO2022094245A1
(en)
|
2020-10-30 |
2022-05-05 |
Vor Biopharma, Inc. |
Compositions and methods for bcma modification
|
CN112553195B
(zh)
*
|
2020-11-05 |
2022-04-05 |
南方医科大学 |
一种用于CRISPR-Cas9定点突变编辑DNMT1基因的试剂及其应用
|
EP4242237A1
(en)
|
2020-11-06 |
2023-09-13 |
Editforce, Inc. |
Foki nuclease domain variant
|
US11512297B2
(en)
|
2020-11-09 |
2022-11-29 |
Inscripta, Inc. |
Affinity tag for recombination protein recruitment
|
JP2023550355A
(ja)
|
2020-11-13 |
2023-12-01 |
ブイオーアール バイオファーマ インコーポレーテッド |
キメラ抗原受容体を発現する遺伝子操作された細胞に関連する方法および組成物
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
WO2022101481A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
WO2022115506A2
(en)
|
2020-11-24 |
2022-06-02 |
University Of Houston System |
Salicylic acid-inducible gene expression compositions and systems for cells
|
EP4251761A1
(en)
|
2020-11-24 |
2023-10-04 |
Keygene N.V. |
Targeted enrichment using nanopore selective sequencing
|
TW202237826A
(zh)
|
2020-11-30 |
2022-10-01 |
瑞士商克里斯珀醫療股份公司 |
基因編輯的自然殺手細胞
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
EP4259651A2
(en)
|
2020-12-14 |
2023-10-18 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
CA3206361A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering Innovations V, Inc. |
In vitro assembly of anellovirus capsids enclosing rna
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
TW202235615A
(zh)
|
2020-12-30 |
2022-09-16 |
美商英特利亞醫療公司 |
工程化之t細胞
|
KR20230146008A
(ko)
|
2020-12-31 |
2023-10-18 |
크리스퍼 테라퓨틱스 아게 |
범용 공여자 세포
|
CN116724109A
(zh)
|
2020-12-31 |
2023-09-08 |
Vor生物制药股份有限公司 |
用于cd34基因修饰的组合物和方法
|
AU2021415461A1
(en)
*
|
2021-01-04 |
2023-08-17 |
Inscripta, Inc. |
Mad nucleases
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
US11332742B1
(en)
|
2021-01-07 |
2022-05-17 |
Inscripta, Inc. |
Mad nucleases
|
KR20230142500A
(ko)
|
2021-01-12 |
2023-10-11 |
마치 테라퓨틱스, 인크. |
콘텍스트-의존적, 이중-가닥 dna-특이적 데아미나제및 이의 용도
|
WO2022170216A2
(en)
*
|
2021-02-08 |
2022-08-11 |
Emendobio Inc. |
Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases
|
US11884924B2
(en)
|
2021-02-16 |
2024-01-30 |
Inscripta, Inc. |
Dual strand nucleic acid-guided nickase editing
|
MX2023009581A
(es)
|
2021-02-16 |
2023-08-23 |
A2 Biotherapeutics Inc |
Composiciones y metodos para tratar tipos de cancer her2 positivos.
|
WO2022180153A1
(en)
|
2021-02-25 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
WO2022187125A1
(en)
*
|
2021-03-01 |
2022-09-09 |
The Regents Of The University Of California |
Methods for generating a crispr array
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
WO2022194908A1
(en)
|
2021-03-17 |
2022-09-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
JP2024511131A
(ja)
|
2021-03-22 |
2024-03-12 |
ライフエディット セラピューティクス,インコーポレイティド |
Dna改変酵素とその活性な断片およびバリアント、ならびに利用の方法
|
EP4320234A2
(en)
|
2021-04-07 |
2024-02-14 |
Astrazeneca AB |
Compositions and methods for site-specific modification
|
WO2022214632A1
(en)
|
2021-04-07 |
2022-10-13 |
Neoplants Sas |
Compositions and methods for indoor air remediation
|
WO2022217086A1
(en)
|
2021-04-09 |
2022-10-13 |
Vor Biopharma Inc. |
Photocleavable guide rnas and methods of use thereof
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
WO2022219175A1
(en)
|
2021-04-15 |
2022-10-20 |
Keygene N.V. |
Mobile endonucleases for heritable mutations
|
JP2024514169A
(ja)
|
2021-04-15 |
2024-03-28 |
キージーン ナムローゼ フェンノートシャップ |
共再生難再生性植物体
|
WO2022221699A1
(en)
|
2021-04-16 |
2022-10-20 |
Beam Therapeutics, Inc. |
Genetic modification of hepatocytes
|
JP2024516168A
(ja)
|
2021-04-22 |
2024-04-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
がんを治療するための組成物および方法
|
WO2022223791A1
(en)
|
2021-04-23 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
CA3218511A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
JP2024518793A
(ja)
|
2021-05-27 |
2024-05-02 |
アストラゼネカ・アクチエボラーグ |
向上した安定性を有するcas9エフェクタータンパク質
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
CA3222023A1
(en)
|
2021-06-01 |
2022-12-08 |
Arbor Biotechnologies, Inc. |
Gene editing systems comprising a crispr nuclease and uses thereof
|
WO2022254337A1
(en)
|
2021-06-01 |
2022-12-08 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
EP4347830A2
(en)
|
2021-06-02 |
2024-04-10 |
Beam Therapeutics Inc. |
Circular guide rnas for crispr/cas editing systems
|
EP4347826A1
(en)
|
2021-06-02 |
2024-04-10 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022261115A1
(en)
|
2021-06-07 |
2022-12-15 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
CA3173953A1
(en)
|
2021-06-11 |
2023-12-10 |
Tyson D. BOWEN |
Rna polymerase iii promoters and methods of use
|
GB202108585D0
(en)
|
2021-06-16 |
2021-07-28 |
Rockend Ltd |
Methods and compositions
|
EP4370676A2
(en)
|
2021-06-18 |
2024-05-22 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing or modifying human genes
|
WO2022272293A1
(en)
*
|
2021-06-23 |
2022-12-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for efficient retron production and genetic editing
|
US20230016422A1
(en)
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
WO2023283585A2
(en)
|
2021-07-06 |
2023-01-12 |
Vor Biopharma Inc. |
Inhibitor oligonucleotides and methods of use thereof
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023283495A1
(en)
*
|
2021-07-09 |
2023-01-12 |
The Brigham And Women's Hospital, Inc. |
Crispr-based protein barcoding and surface assembly
|
TW202317602A
(zh)
|
2021-07-15 |
2023-05-01 |
福瑞德哈金森腫瘤中心 |
嵌合多肽
|
AU2022313315A1
(en)
|
2021-07-23 |
2024-02-08 |
Beam Therapeutics Inc. |
Guide rnas for crispr/cas editing systems
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
AU2022324093A1
(en)
|
2021-08-02 |
2024-02-08 |
Vor Biopharma Inc. |
Compositions and methods for gene modification
|
KR102574819B1
(ko)
|
2021-08-09 |
2023-09-04 |
경상국립대학교산학협력단 |
P34와 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102573952B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
E2와 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102573948B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
Mips1과 이의 상동체 동시 타겟 유전자교정 시스템 및 이의 용도
|
KR102584891B1
(ko)
|
2021-08-09 |
2023-10-04 |
경상국립대학교산학협력단 |
GmIPK1 유전자교정 시스템 및 이의 용도
|
KR102573947B1
(ko)
|
2021-08-09 |
2023-09-01 |
경상국립대학교산학협력단 |
콩 유전자교정 효율 증대를 위한 유전자교정 시스템 및 이의 용도
|
EP4144841A1
(en)
*
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
US11884915B2
(en)
|
2021-09-10 |
2024-01-30 |
Agilent Technologies, Inc. |
Guide RNAs with chemical modification for prime editing
|
PE20240728A1
(es)
*
|
2021-09-21 |
2024-04-15 |
Scribe Therapeutics Inc |
Sistemas de represores de casx disenados por ingenieria genetica
|
WO2023049926A2
(en)
|
2021-09-27 |
2023-03-30 |
Vor Biopharma Inc. |
Fusion polypeptides for genetic editing and methods of use thereof
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
WO2023054350A1
(ja)
|
2021-09-28 |
2023-04-06 |
住友化学株式会社 |
精製ジクロロ酢酸の製造方法
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
IL311572A
(en)
|
2021-09-30 |
2024-05-01 |
Akouos Inc |
Compositions and methods for treating KCNQ4-related hearing loss
|
WO2023059115A1
(ko)
|
2021-10-06 |
2023-04-13 |
주식회사 진코어 |
유전자 편집을 위한 target 시스템 및 이의 용도
|
WO2023064924A1
(en)
|
2021-10-14 |
2023-04-20 |
Codiak Biosciences, Inc. |
Modified producer cells for extracellular vesicle production
|
WO2023064732A1
(en)
|
2021-10-15 |
2023-04-20 |
Georgia State University Research Foundation, Inc. |
Delivery of therapeutic recombinant uricase using nanoparticles
|
US20230241118A1
(en)
|
2021-10-20 |
2023-08-03 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss
|
WO2023070043A1
(en)
|
2021-10-20 |
2023-04-27 |
Yale University |
Compositions and methods for targeted editing and evolution of repetitive genetic elements
|
WO2023068212A1
(ja)
|
2021-10-22 |
2023-04-27 |
公益財団法人東京都医学総合研究所 |
神経変性及び筋萎縮モデル動物
|
US20230293727A1
(en)
|
2021-10-26 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Overexpression of lemd2, lemd3, or chmp7 as a therapeutic modality for tauopathy
|
CA3232470A1
(en)
|
2021-10-27 |
2023-05-04 |
Leah SABIN |
Compositions and methods for expressing factor ix for hemophilia b therapy
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
AU2022381205A1
(en)
|
2021-11-04 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified cacng1 locus
|
CA3236152A1
(en)
|
2021-11-09 |
2023-05-19 |
Vor Biopharma Inc. |
Compositions and methods for erm2 modification
|
GB202117314D0
(en)
|
2021-11-30 |
2022-01-12 |
Clarke David John |
Cyclic nucleic acid fragmentation
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
WO2023105244A1
(en)
|
2021-12-10 |
2023-06-15 |
Pig Improvement Company Uk Limited |
Editing tmprss2/4 for disease resistance in livestock
|
US20230193310A1
(en)
|
2021-12-10 |
2023-06-22 |
Seminis Vegetabe Seeds, Inc. |
Lettuce plants having resistance to downy mildew
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023111173A1
(en)
|
2021-12-16 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
|
WO2023111225A1
(en)
|
2021-12-17 |
2023-06-22 |
Keygene N.V. |
Double decapitation of plants
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
WO2023119135A1
(en)
|
2021-12-21 |
2023-06-29 |
Benson Hill, Inc. |
Compositions and methods for modifying genomes
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023118165A1
(en)
|
2021-12-21 |
2023-06-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023122800A1
(en)
|
2021-12-23 |
2023-06-29 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023139557A1
(en)
|
2022-01-24 |
2023-07-27 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
WO2023144235A1
(en)
|
2022-01-27 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150623A2
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
EP4223877A1
(en)
*
|
2022-02-08 |
2023-08-09 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
System and method for editing genomic dna to modulate splicing
|
WO2023154861A1
(en)
|
2022-02-11 |
2023-08-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
WO2023152351A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus
|
WO2023159103A1
(en)
|
2022-02-17 |
2023-08-24 |
The Board Of Regents Of The University Of Texas System |
CRISPR/SpCas9 VARIANT AND METHODS FOR ENHANCED CORRECTON OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
US20230265421A1
(en)
*
|
2022-02-21 |
2023-08-24 |
Zhuhai Shu Tong Medical Technology Co., Ltd. |
Type ii crispr/cas9 genome editing system and the application thereof
|
WO2023164670A2
(en)
*
|
2022-02-25 |
2023-08-31 |
Duke University |
Crispr-cas9 compositions and methods with a novel cas9 protein for genome editing and gene regulation
|
WO2023164636A1
(en)
|
2022-02-25 |
2023-08-31 |
Vor Biopharma Inc. |
Compositions and methods for homology-directed repair gene modification
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
US20230302423A1
(en)
|
2022-03-28 |
2023-09-28 |
Massachusetts Institute Of Technology |
Rna scaffolded wireframe origami and methods thereof
|
WO2023196816A1
(en)
|
2022-04-04 |
2023-10-12 |
Vor Biopharma Inc. |
Compositions and methods for mediating epitope engineering
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
CN114864002B
(zh)
*
|
2022-04-28 |
2023-03-10 |
广西科学院 |
一种基于深度学习的转录因子结合位点识别方法
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023213831A1
(en)
|
2022-05-02 |
2023-11-09 |
Fondazione Telethon Ets |
Homology independent targeted integration for gene editing
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023217888A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
|
WO2023219657A1
(en)
*
|
2022-05-13 |
2023-11-16 |
Sri International |
Programmable recruitment of transcription factors to endogenous genes
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225410A2
(en)
|
2022-05-20 |
2023-11-23 |
Artisan Development Labs, Inc. |
Systems and methods for assessing risk of genome editing events
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023230578A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating circulating factors
|
WO2023230570A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating genetic drivers
|
WO2023230549A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of tumor suppressors and oncogenes
|
WO2023230573A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of immune responses
|
WO2023230566A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023233342A2
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
WO2023233339A1
(en)
|
2022-06-01 |
2023-12-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
US20230404003A1
(en)
|
2022-06-21 |
2023-12-21 |
Seminis Vegetable Seeds, Inc. |
Novel qtls conferring resistance to cucumber mosaic virus
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024006955A1
(en)
|
2022-06-29 |
2024-01-04 |
Intellia Therapeutics, Inc. |
Engineered t cells
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
JP7152094B1
(ja)
|
2022-06-30 |
2022-10-12 |
リージョナルフィッシュ株式会社 |
tracrRNAユニット、及びゲノム編集方法
|
WO2024006802A1
(en)
|
2022-06-30 |
2024-01-04 |
Pioneer Hi-Bred International, Inc. |
Artificial intelligence-mediated methods and systems for genome editing
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024015925A2
(en)
|
2022-07-13 |
2024-01-18 |
Vor Biopharma Inc. |
Compositions and methods for artificial protospacer adjacent motif (pam) generation
|
WO2024013514A2
(en)
|
2022-07-15 |
2024-01-18 |
Pig Improvement Company Uk Limited |
Gene edited livestock animals having coronavirus resistance
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020597A1
(en)
|
2022-07-22 |
2024-01-25 |
The Johns Hopkins University |
Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026313A1
(en)
|
2022-07-25 |
2024-02-01 |
The Regents Of The University Of California |
Methods of producing and using avian embryonic stem cells and avian telencephalic organoids
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
WO2024026488A2
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a modified transferrin receptor locus
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024036190A2
(en)
|
2022-08-09 |
2024-02-15 |
Pioneer Hi-Bred International, Inc. |
Guide polynucleotide multiplexing
|
WO2024033901A1
(en)
|
2022-08-12 |
2024-02-15 |
LifeEDIT Therapeutics, Inc. |
Rna-guided nucleases and active fragments and variants thereof and methods of use
|
US20240067969A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042489A1
(en)
|
2022-08-25 |
2024-02-29 |
LifeEDIT Therapeutics, Inc. |
Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
|
WO2024042168A1
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024042165A2
(en)
|
2022-08-26 |
2024-02-29 |
UCB Biopharma SRL |
Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
|
WO2024047110A1
(en)
|
2022-08-31 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Method to generate more efficient car-t cells
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
WO2024056659A1
(en)
|
2022-09-13 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Method for treating prostate cancer and other epithelial cancers
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
US20240130341A1
(en)
|
2022-09-29 |
2024-04-25 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
WO2024073751A1
(en)
|
2022-09-29 |
2024-04-04 |
Vor Biopharma Inc. |
Methods and compositions for gene modification and enrichment
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024081736A2
(en)
|
2022-10-11 |
2024-04-18 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024083579A1
(en)
|
2022-10-20 |
2024-04-25 |
Basf Se |
Regulatory nucleic acid molecules for enhancing gene expression in plants
|
WO2024084034A1
(en)
|
2022-10-21 |
2024-04-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
CN115678903B
(zh)
*
|
2022-11-03 |
2024-04-02 |
贵州大学 |
一种白背飞虱Ago1基因、合成dsRNA的方法及其应用
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024095245A2
(en)
|
2022-11-04 |
2024-05-10 |
LifeEDIT Therapeutics, Inc. |
Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024105162A1
(en)
|
2022-11-16 |
2024-05-23 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2024107670A1
(en)
|
2022-11-16 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric proteins comprising membrane bound il-12 with protease cleavable linkers
|
WO2024105633A1
(en)
|
2022-11-18 |
2024-05-23 |
Kyoto Prefectural Public University Corporation |
Compositions for mitophagy induction and uses thereof
|